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CHAPTER 1: ISCHEMIC CONDITIONING: THE CHALLENGE OF PROTECTING THE 
DIABETIC HEART 
(This chapter contains previously published material.  See Appendix B) 
1. Clinical Significance: Acute Myocardial Infarction and Type-2 Diabetes 
Cardiovascular disease (CVD) remains the leading cause of death in the United 
States and globally, with acute myocardial infarction (AMI) accounting for a substantial 
portion of CVD-associated mortality.1  Timely reperfusion is the standard clinical therapy 
for AMI and, although necessary to rescue ischemic tissue, restoration of blood flow can 
paradoxically exacerbate cell death (rather than initiate salvage) in populations of 
ischemic myocytes, a phenomenon termed lethal ischemia-reperfusion (I/R) injury.4-8  
The volume of myocardium rendered necrotic following ischemia-reperfusion (i.e., 
myocardial infarct size) is a primary determinant of mortality and morbidity associated 
with AMI.8-10 However, despite decades of preclinical and clinical investigation aimed at 
elucidating the mechanisms of I/R injury and developing mechanisms-based therapies 
to augment the benefits of early reperfusion and reduce myocardial infarct size, no 
advances have been translated into clinical practice.10-12 
In 1986, Murry et al. made the landmark observation that the heart could be 
‘preconditioned’ or rendered resistant to lethal I/R injury, by exposure to a brief and non-
lethal, antecedent ischemic insult.14  Subsequent studies expanded the paradigm of 
myocardial ‘conditioning’ beyond the phenomenon of ischemic preconditioning to 
encompass postconditioning and remote conditioning.7,15,16  Overwhelming 
experimental evidence, obtained in multiple models and species, has demonstrated that 
all three forms of myocardial conditioning induce potent cardioprotection.7,8,11   However, 
the vast majority (>90%) of these studies have been conducted using healthy, juvenile 
or adult populations that do not manifest the risk factors and comorbid conditions 
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typically seen in patients with CVD and suffering AMI.17  A major, well-established 
independent risk factor for CVD and AMI, the prevalence of which has ~doubled over 
the past 20 years, is type-2 diabetes, 1,18 and there is emerging concern that the efficacy 
of conditioning-induced cardioprotection may be compromised in the diabetic 
heart.6,17,20-22  Our aim in the current review is to focus on this important issue: we 
provide a synopsis of our present understanding of the effect of type-2 diabetes on the 
infarct-sparing effect of ischemic conditioning. 
2. What is Ischemic Conditioning? 
2.1 Definitions and Basic Concepts 
Ischemic conditioning renders the myocardium resistant to I/R injury via the up-
regulation of as-yet incompletely understood, endogenous cardioprotective signaling 
cascades.7,8  There are three permutations of conditioning that differ in terms of the site 
and timing of the brief ischemic stimulus 7.  Classic ischemic preconditioning, as first 
described by Murry and colleagues,14  is initiated by subjecting the heart to 2-4 repeated 
episodes of brief (2-5 minute) ischemia, interrupted by intervening ~5 minute periods of 
reperfusion, before the onset of a sustained ischemic insult.  By contrast, 
postconditioning is not a preischemic intervention but, rather, as described in the 
seminal publication by Zhao et al.,15 is a form of modified reperfusion.  i.e., Blood flow to 
the ischemic myocardium is restored in a stuttered or staccato manner, with a typical 
algorithm of 3-6 cycles of [10-30 seconds of reperfusion interspersed with 10-30 second 
periods of reocclusion], before establishing full and complete reperfusion.  For 
preconditioning and postconditioning, both the protective stimulus (brief antecedent 
ischemia or stuttered reflow) are applied in heart, at the same site and in the same 
vascular territory as the sustained period of ischemia.  Remote conditioning differs 
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importantly from both of the aforementioned strategies in that cardioprotection is evoked 
by brief ischemia applied at a distant site, such as a different and distinct myocardial 
vascular bed (as first reported by Przyklenk et al. 16) or a remote and less vulnerable 
tissue or organ such as skeletal muscle.25  With regard to timing, protection with remote 
conditioning can be achieved when the stimulus is applied before sustained coronary 
occlusion, during the sustained ischemic insult, or at the time of reperfusion (remote 
preconditioning, perconditioning or postconditioning, respectively)7 (Figure 1-1). 
2.2 Reduction of Infarct size: the Hallmark of Ischemic Conditioning 
Despite these temporal and spatial differences, all three facets of ischemic 
conditioning share a common and overarching theme: all are profoundly effective in 
reducing myocardial infarct size beyond that achieved by reperfusion alone7,8.  
Conditioning-induced cardioprotection has, with rare exceptions, been documented and 
Figure 1–1: Schematic diagram
illustrating the key temporal
aspects of preconditioning,
postconditioning, and remote
pre-, per- and postconditioning.
Red boxes denote the
conditioning stimulus.  
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confirmed in countless laboratories and in all models and species that have been 
tested.  There are reports that the benefits of ischemic conditioning (in particular, 
preconditioning and postconditioning) may extend to other pathophysiologic aspects of 
I/R injury, including postischemic myocardial ‘stunning’, arrhythmias, microvascular 
damage and endothelial dysfunction. 21,26,27  However, there is no question that the 
most robust endpoint for the assessment of cardioprotection is infarct size, and the 
established hallmark of ischemic conditioning is its infarct-sparing effect.7,8 (Figure 1-2) 
2.3 Cellular Mechanisms: The Major Players  
In addition to sharing a common primary endpoint – reduction of infarct size – the 
three facets of ischemic conditioning also appear to share common elements in terms of 
cellular mechanisms.  Not surprisingly, the greatest insight has been gained into the 
mechanisms of ischemic preconditioning (comprehensive reviews provided in 6,7,27-30).  
There is a consensus that preconditioning is initiated through ligand-receptor 
interactions including, most notably, stimulation of Gi-protein coupled receptors.  The 
Figure 1–2: Original images of control and postconditioned (PostC) mouse hearts.
Hearts were cut into transverse slices and stained with triphenyltetrazolium chloride; using this
method, viable myocardium is stained red, whereas necrotic myocardium remains unstained
so appears pale. Infarct size was reduced with PostC in normoglycemic C57BL/6J mice. In
contrast, in hearts from db/db mice (model of type-2 diabetes), infarct sizes were comparable
in control and PostC groups. Reprinted with permission from reference 2.  
5 
 
archetypal trigger for preconditioning, first described in 1991, is release of adenosine 
from myocardium rendered ischemic during the brief antecedent ischemic stimulus and 
binding to adenosine A1 or A3 receptors on the cardiomyocyte membranes.31,32  In the 
ensuing years, redundancies in the ligands capable of triggering preconditioning via 
binding to their respective receptors were identified, including (but not limited to) 
bradykinin, opioids, acetylcholine and TNF-α.33-36  Ligand-receptor binding subsequently 
activates multiple signaling cascades in a complex, biphasic and possibly redundant 
manner, following the general paradigm of:  i) initial up-regulation of phosphatidylinositol 
3-kinase (PI3 kinase)/Akt, nitric oxide-mediated activation of protein kinase G (PKG) 
and subsequent activation of the ε isoform of protein kinase C (PKC) during the early 
minutes of sustained ischemia, and ii) receptor re-population and up-regulation of the 
so-called ‘RISK’ (reperfusion injury salvage kinase) and/or ‘SAFE’ (survival activating 
factor enhancement) pathways during the early seconds-minutes following restoration of 
blood flow.30,37-39  There appears to be minimal overlap or intersection between these 
latter two reperfusion-associated signaling cascades: key components of the RISK 
pathway include PI3 kinase-Akt, extracellular signal regulated kinase (ERK), p70S6 
kinase and glycogen synthase kinase 3β (GSK3β), while the pivotal constituents of the 
SAFE pathway are janus activated kinase (JAK) and signal transducer and activator of 
transcription (STAT).6,7,27-30,38,39  Nonetheless, both pathways converge on the 
mitochondria, the proposed end-effector of ischemic preconditioning, with specific 
molecular targets including the mitochondrial adenosine triphosphate-sensitive 
potassium (KATP) channel, mitochondrial connexin 43, and, most notably, the 
mitochondrial permeability transition pore (mPTP).28,40-43  Cardioprotection is 
purportedly conferred by a resultant stabilization of mitochondrial membranes (including 
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suppression of mPTP opening) and better maintenance of mitochondrial integrity.6,7,27-30 
The discovery of infarct size reduction with postconditioning, and observations of 
a comparable magnitude of cardioprotection with both preconditioning and 
postconditioning, provided compelling and provocative evidence that pretreatment – and 
up-regulation of kinase signaling at the onset of ischemia – is not required to render the 
heart resistant to I/R injury.15  Moreover, the lack of an additive effect of combined 
administration of preconditioning + postconditioning suggests that common (or 
redundant) reperfusion-associated mechanisms may underlie the infarct-sparing effect 
of the two interventions.15  Indeed, receptor-mediated up-regulation of the RISK and/or 
SAFE pathways, culminating in stabilization of mitochondria (with an emphasis on 
inhibition of mPTP opening) are hypothesized to play critical roles in the reduction of 
infarct size achieved with postconditioning.6,7,21,28,30,44-46 
Perhaps not surprisingly, the three common themes of G-protein coupled 
receptor stimulation on myocyte membranes, activation of multiple kinases including 
members of the RISK and/or SAFE pathways, and mitochondria as end-effectors have 
also been implicated as key mechanistic components of remote conditioning (reviewed 
in references 7,47-50).  There is, however, an inherently unique aspect of remote 
conditioning not shared by pre- and postconditioning: the cardioprotective signaling 
cascades are initiated by communication or transfer of a protective signal from the site 
of the conditioning stimulus to the heart.  Details concerning the identity of the signal(s) 
and mode of communication remain elusive, but two leading theories are under 
investigation: remote conditioning may be triggered by blood- or perfusate-borne 
transport of one or more unknown humoral factor (possibly including a small, <15 kDa 
hydrophobic molecule)51-53, and communication via neuronal stimulation. 7,47-55  Of note, 
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these two hypotheses are not mutually exclusive, are in all likelihood model-dependent, 
and, in at least some models, both humoral and neuronal communication may be 
involved. 7,47,48,56,57 
2.4 Ancillary and Alternative Mediators of Conditioning-induced Cardioprotection 
As summarized in the preceding paragraphs, intensive interest and attention has 
focused on the involvement of RISK and SAFE signaling to the infarct-sparing effect of 
ischemic pre-, post- and remote conditioning.  However, additional and less well-
characterized mediators have also been postulated to contribute to conditioning-induced 
cardioprotection, either in concert with or as possible alternatives to the RISK and SAFE 
cascades.  For example, isoforms of PKC (in particular, PKCε) may play a broader role 
in conditioning-induced cardioprotection, beyond the well-described early activation 
following brief preconditioning ischemia: PKC has been implicated as a component of 
kinase signaling initiated in response to both postconditioning and remote 
preconditioning. 29,58-62  Generation of low, sub-lethal levels of reactive oxygen species 
(ROS) and signaling via nitric oxide have, similarly, been proposed to integrate with 
both PKC and the RISK and STAT pathways as mediators of pre- and 
postconditioning.30,59,60,62-64  
A long-standing concept that may be relevant to the issue of cardioprotection in 
diabetic cohorts, particularly for ischemic preconditioning, is that alterations in 
myocardial metabolism play a causal role.  Metabolic hallmarks of cardiac ischemia 
include the rapid (within seconds-minutes) shift from aerobic to anaerobic metabolism 
and the resultant, progressive temporal decline in myocardial ATP concentration as 
ATP synthesis via anaerobic glycolysis is insufficient to meet the diminished, residual 
energy consumption of the ischemic tissue. 65  The first report of infarct size reduction 
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with preconditioning was accompanied by evidence of an increase in metabolic 
efficiency: i.e., preconditioning slowed myocardial energy demand during the 
subsequent period of sustained ischemia, thereby attenuating the rate of ATP utilization 
and reducing the rate of anaerobic glycolysis.14,66,67  Ensuing studies argued against the 
concept of a cause-and-effect relationship between reduced energy demand during 
prolonged ischemia and infarct size reduction with preconditioning.68  Nonetheless, 
there is evidence for a mechanistic link between metabolism and preconditioning-
induced cardioprotection.  Ischemic preconditioning is associated with an increase in 
glucose uptake during sustained ischemia, an effect that has been attributed to: i) co-
activation of Akt and AMP-activated protein kinase (AMPK: the ‘metabolic master 
switch’ that responds to ATP depletion and an increase in the ratio of ADP/ATP); ii) 
translocation of the glucose transporter protein GLUT4 to the cardiomyocyte surface; 
and iii) subcellular redistribution of hexokinase to mitochondria, where it phosphorylates 
and facilitates sequestration of glucose.69-76  This metabolic signaling is purportedly 
required for the infarct-sparing effect of ischemic preconditioning,69-73 and has been 
implicated to play a secondary role in postconditioning.77 
3. Cardiac Consequence of Diabetes 
3.1 The Big Picture: Diabetes, Cardiovascular Disease and Acute Myocardial Infarction 
The successful clinical translation of novel interventions to attenuate myocardial 
1/R injury has been identified as a major unmet need.10-12  This issue is of particular 
relevance and importance to patients with type-2 diabetes, as underscored by: i) the >2-
fold greater incidence of CVD, acute coronary syndromes and AMI in this patient cohort; 
ii) evidence of larger infarct sizes and exacerbated necrotic and apoptotic cell death; 
and thus, perhaps not surprisingly, iii) a 2- to 4-fold greater incidence of CVD-related 
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mortality in diabetic versus non-diabetic subjects.1,78-89  Indeed, CVD is the leading 
cause of death and disability among diabetics, a poor prognosis that has not been 
appreciably influenced by the current trend of an overall reduction in mortality 
associated with AMI.1,78,79,88,89  Recent statistics reveal that, at present, Americans have 
an estimated ~40% lifetime risk for the development of diagnosed diabetes, and a 
sustained increase in the incidence of type-2 diabetes in the USA and worldwide is 
predicted for the next 20-30 years.  This anticipated escalation in the numbers of 
patients with diabetes may have the potential to diminish the gains that have been 
made attenuating the overall prevalence of CVD-related death.1,90-92 
3.2 The Cellular/Molecular Perspective 
The hallmarks of type-2 diabetes are insulin resistance and accompanying 
metabolic dysregulation.  Reduced insulin sensitivity has both direct effects on glucose 
uptake and insulin-mediated signaling in cardiac cells, and indirect cellular effects that 
are secondary to the accompanying hyperglycemia, hyperinsulinemia and 
hyperlipidemia.93-96  Most importantly, in terms of cardioprotection, type-2 diabetes has 
been associated with impaired PI3 kinase/Akt signaling (components of both insulin 
signaling and the RISK pathway) and GLUT4 protein expression and/or translocation, 
as well as defects in AMPK and, indeed, essentially all kinases proposed to contribute 
to the infarct-sparing effect of ischemic conditioning.  For example, impaired 
phosphorylation of PKC, PI3 kinase/Akt, ERK, STAT3, and GSK-3β has been described 
in diabetic hearts, possibly due to reported increases in activities of multiple 
phosphatases including phosphatase and tensin homolog (PTEN), MAPK phosphatases 
(MKPs) and protein phosphatase-2C (PP2C).  There is evidence to suggest that 
downstream targets and proposed end-effectors of conditioning-induced 
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cardioprotection are also modified by type-2 diabetes, including alterations in 
expression and activity of mitochondrial KATP channels and increased propensity of 
mPTP opening in response to increased intracellular Ca2+ concentrations in the diabetic 
myocardium.96-102  Although these insights have, not surprisingly, been largely derived 
from genetic rodent models of type-2 diabetes, including db/db and ob/ob mice and 
strains of fatty and lean rats (Zucker Fatty, Otsuka Long-Evans-Tokushima fatty and 
Goto-Kakizaki),96-100 analysis of myocardial tissue samples collected from diabetic 
patients at the time of cardiac surgery have yielded corroborative results.101,102 
4. Diabetes, Infarct Size and Ischemic Conditioning 
4.1 Diabetes and Ischemic-Reperfusion Injury 
The effect of type-2 diabetes on the infarct-sparing effect of ischemic conditioning 
has, almost exclusively, been assessed in the aforementioned rodent models.  
Accordingly, meaningful discussion of conditioning-induced cardioprotection in these 
models first requires an understanding of the effect of type-2 diabetes on infarct size in 
untreated control animals.   
In contrast to the clinical consensus that diabetes is associated with larger infarct 
sizes and poor outcomes when compared with non-diabetic patients,1,78-89 data obtained 
in preclinical models is mixed: diabetes has been reported to increase, decrease or 
have no effect on cardiomyocyte death.22,103-105  These disparate outcomes have been 
attributed to multiple factors, including: i) the duration of the diabetic state at the time of 
experimentation (with short-term diabetes more typically associated with an apparent 
reduced sensitivity to I/R injury); ii) differences over time or among models in levels of 
insulin and fatty acids; and iii) the presence or absence of obesity.22,104,105  The 
definitions of ‘short-term diabetes’, hyperinsulinemia, hyperlipidemia, etc., and precise 
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relationships of these factors with myocardial infarct size, are nebulous.  However, it is 
important to emphasize: the translational relevance of experimental models 
characterized by a reduced sensitivity of the diabetic heart to I/R injury is considered to 
be questionable.104 
4.2 Ischemic Conditioning in Models of Type-2 Diabetes: is Efficacy Maintained? 
A PubMed search of the current literature reveals that, as a conservative 
estimate, there are >2,500 publications on ischemic pre-, post- and remote conditioning 
in which myocardial infarct size (the ‘gold standard’ of conditioning-induced 
cardioprotection) was among the primary endpoints.  Remarkably, <0.5% of these 
papers have specifically investigated the infarct-sparing effect of ischemic conditioning 
in models of type-2 diabetes – a statistic that is extraordinary given the well-
documented, profound consequences of diabetes on cardiac pathophysiology.  
Among the small number of studies that have addressed this issue, a spectrum 
of rat and mouse models of type-2 diabetes have been utilized (Table 1-1).  
Nonetheless, irrespective of the model used and variations in study design, there is an 
emerging consensus: both pre- and post-conditioning either fail to reduce infarct 
size,100,106-111 or the efficacy of conditioning is attenuated such that an amplified stimulus  
(i.e., an increased number of episodes of preconditioning ischemia) is required to evoke 
protection.112-114.  Loss of conditioning-induced cardioprotection has been described in 
both lean and obese models type-2 diabetic rat models 106 and in obese rats before the 
onset of significant hyperglycemia107.  Moreover, similar outcomes (a diminished 
responsiveness to the infarct-sparing effect of pre- and postconditioning) have also 
been reported in models of type-1 diabetes,17,20-22,72,108,115-123 suggesting that the 
refractoriness of the diabetic heart to ischemic conditioning is not a simple consequence 
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Table 1–1: Effect of type-2 diabetes on infarct size reduction with ischemic 
conditioning 
Author Model Reduction of 
infarct size? Comments/mechanistic insights? 
PRECONDITIONING 
Kristiansen1  Rat: Zucker Fatty No Protection lost in both lean and obese models. 
Rat: Goto‐Kakizaki No No mechanism proposed. 
Tsang3 Rat: Goto‐Kakizaki Attenuated 
Efficacy attenuated; amplified preconditioning 
stimulus required to achieve protection. Impaired 
Akt phosphorylation. 
Katakam4 Rat: Zucker Fatty No 
Protection lost before development  
of hyperglycemia. 
Impaired activation of mitochondrial  
KATP channels. 
Hausenloy5 Rat: Goto‐Kakizaki Attenuated 
Efficacy attenuated: amplified  
preconditioning stimulus required to achieve 
protection. 
Whittington6,7 Rat: Goto‐Kakizaki 
Attenuated Amplified preconditioning stimulus was 
protective in 3 and 8 month old rats. 
No 
Complete loss in efficacy in 12 and 18 month old 
rats. Impaired Akt phosphorylation due to 
chronic up‐regulation. 
POSTCONDITIONING 
Wagner Rat: WOKW No Impaired ERK, GSK‐3‐β phosphorylation 
Bouhidel8 Mouse: ob/ob No Impaired Akt, ERK, p70S6 kinase, AMPK phosphorylation 
Przyklenk2 Mouse: db/db No Impaired ERK phosphorylation 
Zhu9 Mouse: db/db No Loss of protection associated with differential regulation of mitochondrial proteome 
Oosterlinck10 Mouse: ob/ob Attenuated No mechanism proposed. 
REMOTE 
PRECONDITIONING 
No studies 
published   
 
of hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity or, in all likelihood, any 
single pathophysiological feature of the disease.  Nascent mechanistic insight has, 
however, been obtained into the cellular mechanisms that may contribute to the 
compromised efficacy of ischemic conditioning in diabetic models.  Perhaps not 
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surprisingly, the complete or partial failure of pre- and postconditioning to limit infarct 
size in models of type-2 (and type-1) diabetes has largely been attributed to defects in 
RISK and AMPK signaling, with desensitization or impaired activation of multiple 
kinases (including PI3 kinase/Akt, ERK, p70S6 kinase, and/or GSK3β), possibly due to 
augmented activities of MKPs and other phosphatases, all having been implicated to 
play a role (Table1-1)).17,21,22,100,108-110,112,121  Potential diabetes-associated defects in 
mitochondrial end-effectors have also been identified, including impaired activation of 
mitochondrial KATP channels 107,111. 
Finally, there is a notable and fundamental gap in our current knowledge of the 
efficacy of ischemic conditioning in models of type-2 diabetes.  All previous discussion 
has focused exclusively on pre- and postconditioning; to date, no published studies 
have utilized remote conditioning as the cardioprotective trigger (Table1-1).  There is, 
however, one piece of evidence that diabetes may have a complex, confounding effect 
on the production or release of the as-yet unidentified humoral factor(s) from the site of 
the conditioning stimulus124.  A model of ‘transferred’ protection was used, in which the 
conditioning stimulus (brief repeated episodes of limb ischemia) was applied to diabetic 
and non-diabetic patient cohorts, serum was collected, dialyzed and administered to a 
remote target (isolated buffer-perfused rabbit hearts), and the hearts were then 
subjected to a sustained period of ischemia.  For both cohorts, serum collected after the 
conditioning stimulus rendered the rabbit hearts resistant to infarction: i.e., type-2 
diabetes per se did not preclude the infarct-sparing effect of remote conditioning.  
However, in the subset of diabetic subjects with peripheral neuropathy, the transferred 
serum failed to reduce infarct size in acceptor rabbit hearts, implicating the requisite 
involvement of a diabetes-sensitive neurogenic component in this model of humorally-
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mediated remote conditioning.124  The consequences of type-2 diabetes in standard in 
vivo models of remote conditioning, and the concept that persistent efficacy of remote 
conditioning in diabetic models may depend on the intact innervation of the effector 
organ, are topics of ongoing study by our group and others (Figure 1-3). 
 
Figure 1–3: Schematic diagram
underscoring the paucity of
available data on the efficacy of
ischemic conditioning in the
setting of diabetes. PubMed queries
were performed in September 2014
using the search terms ‘ischemic
preconditioning and heart’ (A),
‘postconditioning and heart’ (B) and
‘remote ischemic preconditioning and
heart’ (C), with and without the
addition of the term ‘diabetes’.
Studies conducted in diabetic models
in which infarct size (the gold
standard of ischemic conditioning)
was among the primary endpoints are
highlighted.  
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4.3 Initial Insight: Ischemic Conditioning in Diabetic Patients 
The wealth of preclinical evidence documenting reduction of infarct size with pre-, 
post- and remote conditioning has provided the groundwork and rationale for ongoing 
efforts to translate the concept of endogenous conditioning-induced cardioprotection for 
the clinical treatment of myocardial I/R injury.8,10-12,125  As preconditioning is, by 
definition, a pretreatment – thereby limiting its potential for clinical use to planned 
ischemic events such as cardiac surgery and elective percutaneous intervention (PCI) – 
current attention is focused largely on postconditioning and remote conditioning.  
Results from ~40 Phase II clinical trials have been reported, and large Phase III trials 
are in progress (reviewed in references 8,125).  Overall, the data have been mixed: 
~60% of the studies observed significant reductions in cardiac enzyme release and 
other surrogate endpoints reflecting myocardial infarct size in conditioned cohorts 
versus controls, while the remainder reported either no effect or exacerbated 
outcomes.8,125.  In addition, recent meta-analyses of pooled data from multiple trials 
underscored the variability among studies and concluded that, at present, there is 
borderline evidence, or no evidence, for cardioprotection with either postconditioning or 
remote conditioning.126,127 
In addition to differences in patient demographics and enrollment criteria, 
protocol logistics (including the number and timing of the conditioning stimuli and 
duration of sustained ischemia), choice of endpoints, etc., extrapolation of the results 
obtained in preclinical models of type-2 diabetes suggest that two related factors – the 
confounding effects of diabetes, together with differing proportions of diabetic patients 
among studies – may also contribute to the aforementioned variability.  Indeed, in an 
effort to mitigate this concern, some investigators have prospectively excluded the 
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enrollment of diabetic patients.128-131  Initial evidence appears to support the concept 
that conditioning-induced cardioprotection may be impaired or lost in patients with 
diabetes.  For example, in two clinical trials in which prospective subset analyses were 
performed and cardiac enzyme release served as the surrogate for infarct size, 
preconditioning (triggered by prodromal angina) had no beneficial effect, while 
postconditioning tended to exacerbate myocardial injury in diabetic cohorts.132,133  In 
addition, in a third trial evaluating the efficacy of remote conditioning administered 
following elective PCI, the incidence of post-procedural MI was significantly increased in 
patients with versus without diabetes.134  Finally, in an ex vivo analysis, preconditioning 
attenuated hypoxia-reoxygenation-induced cell death in human atrial samples harvested 
from non-diabetic patients at the time of cardiac surgery, but failed to render atrial tissue 
resistant to injury in samples obtained from patients with type-2 diabetes.135    
5. Summary and Future Directions 
Despite the paucity of studies conducted in preclinical models of type-2 diabetes 
in which myocardial infarct size was among the primary endpoints (Table1-1), a 
consensus is emerging: the diabetic rodent heart is refractory to the profound infarct-
sparing effect of preconditioning, postconditioning and, possibly, remote conditioning.  It 
could be argued these data may be of limited clinical relevance, given the overt 
simplicity of the mouse and rat models: the duration of diabetes is comparatively acute 
(on the order of weeks, rather than months-years), the models do not mimic the multiple 
comorbid conditions seen in substantial subsets of patients, and preclinical protocols 
typically do not incorporate the battery of pharmacologic agents that would be 
administered to patients as standard clinical care for both AMI and the management of 
hyperglycemia.  Nonetheless, although far from conclusive, the initial clinical data 
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appear to corroborate the preclinical results. 
Does ischemic conditioning have the potential to achieve the as-yet unmet 
clinical challenge of attenuating myocardial ischemia-reperfusion injury and improving 
outcome in patients post-MI?  And, if so: is the efficacy of conditioning-induced 
cardioprotection compromised in diabetic patients?  Definitive resolution of these issues 
will require the successful execution of Phase III clinical trials that are prospectively 
designed with sufficient statistical power to discern the presence versus absence of an 
infarct-sparing effect of ischemic conditioning in stratified subgroups of patients with and 
without type-2 diabetes. 
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CHAPTER 2: EXOSOMES IN REMOTE PRECONDITIONING 
1. A Brief History of Exosomes 
Exosomes are cell-derived, membrane particles associated with cell-to-cell 
communication.  Emerging evidence has implicated them in health, disease and 
medicine, thus fueling a rapidly growing field. Recently, exosomes have been implicated 
in the humoral component of remote preconditioning, and investigating exosomes could 
contribute to our understanding of the communication mechanism of this 
cardioprotective phenomenon.  The biology of exosomes will be discussed, with an 
emphasis on their history in treating AMI, and newly described role in remote 
preconditioning. 
In 1967, Wolf et al. described lipid-rich particles, or “platelet dust” that promote 
hemostasis, present in the serum after removal of platelets.136  In the mid-80s, two 
groups lead by Johnstone and Stahl described similar vesicles released when 
endosomes fuse with the plasma membrane in reticulocytes.137,138  Pan et al. and 
Harding et al. observed internalization of transferrin receptors by endocytosis, followed 
by inward budding of the endosomal limiting membrane, resulting in formation of 
intraluminal vesicles.  Endosomes containing vesicles (commonly known as 
multivesicular bodies) then fused with the plasma membrane releasing the intraluminal 
vesicles containing transferrin receptors into the extracellular space.139,140  
Externalization of these vesicles appeared to involve the reversal of the endocytic 
pathway where, instead of lysosomal delivery, they are exocytosed, thereby leading to 
the name exosomes (a term originally proposed to describe small plasma membrane 
derived vesicles in 1981).141,142  As with the lysosomal pathway, exosomes were initially 
identified exclusively as a method of waste disposal; exfoliating unwanted membrane 
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proteins, such as reticulocyte transferrin receptors.  More recently however, exosomes 
are being implicated in a growing list of physiological and pathophysiological processes.  
A PubMed search (February 2017) of the term “exosome” retrieved >5800 papers 
(Figure 2-1).   We added qualifying terms to the query, such as “cancer” or “immune”, to 
roughly illustrate the context of exosomes research. 
2. Exosomes in a Nutshell 
Extracellular vesicles are categorized into multiple subgroups, of which the most 
widely studies are apoptotic bodies, microvesicles and exosomes.  Extracellular 
vesicles are functionally and morphologically distinct and are ideally classified in terms 
of the mechanism of biosynthesis and physical characteristics, such as size.  By 
definition the term exosome refers strictly to extracellular vesicles formed in endosomes 
and released by exocytosis.  Experimentally, subclasses of extracellular vesicles are 
defined by the method of isolation.  Exosomes are distinct from other extracellular 
vesicles in their biosynthesis, communication and physical characteristics, which will be 
Figure 2–1: The focus of studies in exosome literature. A literature search of PubMed
revealed the occurrence of the term “exosome” with another term. “Other” represents the number
of studies that contain the term “exosome” without one of the terms listed above. 
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briefly introduced (Figure 2-2). 
 
2.1 Biosynthesis, Release and Uptake 
Exosomes are formed as intraluminal vesicles in the endosomal pathway. 
Endosomes originate by budding off the trans-Golgi network or the plasma membrane 
into the cytoplasm.  As these organelles mature, intraluminal vesicles are formed by 
inward budding of the endosomal limiting membrane and become exosomes when 
released by the cell.143  The process of cargo-loading and vesiculation are regulated 
processes, resulting in formation of multivesicular bodies with discrete populations of 
intraluminal vesicles.  Posttranslational modification of proteins (especially 
ubiquitination) and localizing sequences in RNA are reported to play a role in sorting 
cargo into the vesicles.  Lipid raft formation in the endosomal limiting membrane by 
protein-mediated lipid modifications and lateral segregation of membrane components 
assist in the budding process of vesicle formation.  Seminal studies demonstrated that 
endosomal sorting complex responsible for transport (ESCRT) protein complexes are 
central in sorting cargo, membrane budding/scission and membrane trafficking, though 
Figure 2–2: Extracellular
vesicle size distribution and
mechanism of release.
Exosomes, microvesicles and
apoptotic bodies are distinct
vesicles found in the
extracellular space. Although
vesicles, particularly exosomes,
have been defined by their size,
it is becoming evident that there
may be significant overlap. 
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subsequent studies have uncovered ESCRT-independent biosynthetic pathways.144-147  
Cluster of differentiation (CD) and small integral membrane protein of lysosomes and 
late endosomes (SIMPLE) proteins have been proposed as ESCRT-independent 
mediators of exosome biogenesis.148-150  Additionally, cholesterol, ceramide and 
phosphatidic acid are integral components in lipid rafts which are considered necessary 
(and possibly sufficient) for forming intraluminal vesicles.151,152  
Trafficking endosomal membranes is a constitutive and regulated process, which 
carries intraluminal vesicles to the plasma membrane for secretion or to lysosomes for 
degradation.  Rabs are a family of small GTPases essential for endosomal membrane 
trafficking, regulating transport along actin filaments and microtubules by molecular 
motors (kinesin and dynein).  Rabs have also been implicated in intraluminal vesicle 
budding and multivesicular body fusion with the plasma membrane.  More than 70 Rab 
proteins regulate vesicular trafficking in eukaryotes, emphasizing the complexity of this 
process [Reviewed by Stenmark, 2009].153  After translocation to the cell periphery, 
multivesicular bodies fuse with the plasma membrane resulting in externalization of 
intraluminal vesicles.  Membrane fusion is a three step process extensively 
characterized in synapse vesicles and secretory granules.  Initially, the donor 
membrane (multivesicular body) is (1) tethered to the target membrane (plasma 
membrane).154,155  Tethering factors are bound to the inner leaflet of the target 
membrane and associate with factors on the donor membrane, which loosely and 
specifically juxtapose the membranes.  After tethering, SNARE protein complexes on 
opposing membranes bind to one another and initiate membrane (2) docking, where the 
vesicular and plasma membranes become tightly associated.156  Following docking, 
SNAREs catalyze (3) fusion of the two membranes.  Although the process remains 
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largely enigmatic, fusion likely involves formation of a fusion pore by a “zipper” action 
facilitated by the SNAREs.157  
The general paradigm for regulated uptake suggests that membrane signatures 
anchor vesicles to the target membrane on recipient cells, which subsequently 
internalize the exosome or its contents.158,159  Membrane protein interactions have been 
illustrated to facilitate recruitment and uptake.160,161  For example, tetraspanins are cell 
surface proteins involved in cell adhesion that have been implicated in exosome 
uptake.162,163  The Zöller lab reported that the N-terminal of tetraspanin 8 is necessary 
for exosome uptake into endothelial cells, which may be involved in cancer-activated 
angiogenesis.162,164  Proteoglycans, integrins and immunoglobulins are other common 
protein signatures implicated in exosome uptake.165-167  Internalization of exosomes or 
Figure 2–3: Exosome biosynthesis and uptake. Exosomes are formed in endosomes as 
intraluminal vesicles and subsequently secreted from the source cell by exocytosis into the 
extracellular space, illustrated in the cell on the left. There are multiple mechanisms involved 
with exosome uptake, illustrated in the cell on the right. 
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its contents can be mediated through multiple pathways, most of which are energy 
dependent, including lipid raft-mediated and clathrin-mediated endocytosis, 
phagocytosis and micropinocytosis168-172  (see Figure 2-3). 
Exosome biosynthesis, release and uptake are becoming recognized as highly 
regulated processes.  The first evidence of regulation is arguably reported by Harding et 
al. and Pan et al. in their seminal studies with reticulocytes, reporting that transferrin 
receptors were selectively shed from the plasma membrane through exosome 
secretion.137,138  Three decades later, there is convincing evidence of exosome 
regulation, which takes place at nearly every step and may be modified by a variety of 
stimuli, including extracellular signaling,173 calcium concentration,174,175 pH,176 oxidative 
stress177 and temperature.178  Cellular uptake of exosomes can be cell type-selective or 
prioritized, a trait that is being explored for use in synthetic exosomes as homing 
signals.163  Exosome characteristics may be altered in disease states, especially 
cancer.179  Studies report that circulatory exosomes are increased by risk factors for 
cardiovascular disease including type-2 diabetes,180 obesity,181 and senescence.182 
Importantly, transient ischemia has been reported to effect exosome secretion, which 
will be discussed in section 4-2: Exosomes in Remote Preconditioning.  
2.2 Physical and Molecular Characteristics 
Exosomes have diverse characteristics, particularly with respect to molecular 
composition.  Exosome composition is determined by a variety of factors including their 
cellular origin (i.e., derived from platelets versus endothelial cells versus muscle cells, 
etc.), subcellular localization and cell activation.  ExoCarta, a public bioinformatics 
platform, has compiled >22,000 proteins, RNAs and lipids (October 2016) discovered in 
exosomes.  Ultimately, the diversity in composition and other physical features results in 
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a heterogeneous population of vesicles which are difficult to define.  Moreover, many of 
these properties are not exclusive to exosomes. Nonetheless, exosomes are classified 
by a subset of common properties, introduced below. 
Exosomes are most commonly classified by size (30 to 150nm), as typically 
measured with electron microscopy or nanoparticle tracking analysis.  Early electron 
microscopy suggested that exosomes are cup shaped183, however improved sample 
preparation revealed their innate, spherical structure.184  Exosomes have two functional 
compartments; the vesicle membrane and the cytosolic lumen.  The exosomal 
membrane is derived from the parent cell plasma membrane and although there are 
similarities in composition142, the lipid and protein content is modified.  Many studies 
report that exosome membranes have the properties of lipid rafts; high liquid-order185, 
enrichment with cholesterol, sphingomyelin and ganglioside GM3186,187 and markers for 
detergent resistant domains.188,189  Additionally, exosomal membranes, unlike their 
parent cell membrane and other nano-vesicles, are not asymmetrical and 
phosphatidylethanolamine is distributed in both the inner and outer membrane leaflet.190  
Phosphatidylserine has also been reported in the outer leaflet allowing detection with 
annexin-5, however these findings are inconsistent and possibly a trait specific to parent 
cell-type.191,192  
Exosomes are also regularly classified by marker proteins.  Exosome formation 
is a distinct process; accordingly, the presence of proteins from the biosynthetic 
pathway (flotillin, Alix, TSG101) are considered to be hallmarks that distinguish 
exosomes from other extracellular vesicles.  Other structural and transmembrane 
proteins such as the tetraspanins CD63, CD9 and CD81 are also common exosome 
markers.  Intraluminal vesicles encapsulate cytosol during formation and consequently 
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exosomes contain small molecules present in the cytosol such as metabolites.193  
Nonetheless, there have been no signatures established by proteomic, metabolomics, 
lipidomic or transcriptomic studies that exclusively distinguish exosomes from other 
extracellular vesicles.  
3. Methods for the Isolation and Characterization of Secreted Exosomes 
A large variety of experimental techniques have been developed to address the 
demands in exosome research, however techniques (especially isolation) may affect 
experimental outcome.  To promote the use of suitable techniques the field has been 
divided into three subcategories based on experimental objectives; discovery, 
diagnostics and preparative research.13  In the interest of brevity, experimental 
techniques will be introduced, with a focus on techniques relevant to this study. 
3.1 Methods and Techniques: Isolation 
Exosomes have been isolated using multiple methods, with the goal of yielding a 
vesicular population of functional/intact exosomes without contamination (e.g. devoid of 
protein aggregates and non-exosome vesicles).  Current techniques have been 
combined and refined in an attempt to improve isolation, however the process of 
isolating exosomes has limitations and no perfect method has been developed.  The 
most frequently used method of isolation is differential centrifugation, which isolates 
particles by size, density and sedimentation distance.  Exosomes are among the 
smallest extracellular vesicles, and thus require the highest force for sedimentation.194  
Large structures are sedimented by low force centrifugation (2000xg for whole cells 
followed by 10,000-20,000xg to sediment debris and large vesicles) and exosomes are 
subsequently pelleted by high force ultracentrifugation (100,000-120,000xg for 1-2 
hours).  Sucrose density gradients or cushions separate particles by buoyant density to 
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improve isolation specificity, however the purity may still be inadequate for certain 
applications.  Exosomes can be isolated by size exclusion, where molecular weight 
cutoff ultrafiltration or chromatography is used to separate particles by size.  
Commercial isolation kits have been developed, utilizing polymeric precipitation and low 
force centrifugation to sediment exosomes.  Membrane proteins can also be targeted 
for immunoaffinity capture to isolate exosomes with more specificity, which is valuable 
in optimizing the purity of the preparation.194 
3.2 Methods and Techniques: Characterization 
Exosomes are characterized based on morphology (size, shape, etc.), 
biogenesis, function and composition.  In characterizing exosomes, the technique used 
to study the particles will depend on the characteristics of interest. Electron microscopy, 
dynamic light scattering, atomic force microscopy and nanoparticle tracking analysis are 
used to provide insight into exosome concentration, size distribution, and shape.195  
Electron microscopy is valuable in determining the size of exosomes, and has provided 
evidence of the mechanism of biogenesis, release and uptake of exosomes.139  With 
regard to function, fluorescent lipid dyes and membrane permeant dyes have been used 
to monitor exosome uptake with confocal microscopy,159 while proteomic, lipidomic and 
transcriptional analyses have been employed to reveal the molecular composition of 
vesicles.  
Although there is an expanding repertoire of techniques, experimental limitations 
have impaired our understanding of exosomes, resulting in inconsistencies in the 
literature.  The International Society for Extracellular Vesicles has called for technical 
requirements in an attempt to standardize experimentation and unite the extracellular 
vesicle field.196  In the meantime, understanding the techniques used to isolate and 
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characterize a particular extracellular vesicle type should take precedence over how 
they are classified.  The experimental limitations are discussed in 3.3 Experimenting 
with Exosomes: Technical Limitations.  
3.3 Experimenting with Exosomes: Technical Limitations  
In this chapter, we have presented “common properties” of exosomes, however 
experimental limitations may influence our general understanding of exosomes and how 
they are defined or classified.  Understanding these limitations is important for designing 
studies, interpreting data and comparing results.  Perhaps the most important 
experimental limitations involve isolation techniques, because inefficient collection of 
exosomes could affect subsequent characterization or quantification.  Quality and yield 
are the priority when isolating exosomes; however no isolation technique is ideal.2,3  For 
example, in this dissertation work we use differential ultracentrifugation, which is the 
most common isolation technique.  Although ultracentrifugation reliably isolates 
exosomes, there are two major limitations; (1) Non-exosome particles contaminate the 
exosome rich pellet,13,2 and (2) the traditional ultracentrifugation will not sediment 
exosomes entirely, resulting in a partial exosome preparation.19  Characterization and 
quantification of exosomes is another process that is limited by experimental 
techniques.  A commonly measured characteristic in exosome research is vesicle 
quantity or concentration.  Quantifying exosome is difficult however, because often 
times contaminating proteins and non-exosome vesicles will obscure the true exosome 
measurements.23  Additionally, exosome markers will provide qualitative assessment of 
exosome content, however because they are not exclusive to exosomes nor 
ubiquitously present in all exosomes, they cannot be used for accurate quantification.24  
In addition to these examples, there are many other techniques for studying exosomes 
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and their inherent limitations can be minimized by choosing the appropriate technique 
based on experimental objectives. 
4. Exosomes: A Delivery Service for Remote Preconditioning 
Exosomes have been purported to be cardioprotective in the context of treating 
ischemia reperfusion injury.197-199  However, in 2014, Giricz et al. were the first to 
demonstrate that exosomes are involved in remote preconditioning.200  
4.1 Treating Myocardial Infarction with Exosomes 
Exosomes were recognized for cardioprotective capabilities before their 
implication in remote preconditioning.  In the early 2000s, stem cells garnered attention 
for their potential in regenerating damaged tissue, including infarcted myocardium.  
Initial theories predicted that implanted stem cells would differentiate into cardiac cells, 
replace damaged tissue and improve function.201-203  Indeed, stem cells have been 
shown in some studies to favorably modify post-infarction left ventricular remodeling, 
promote neo-vascularization and improve cardiac function. 204-207  However, subsequent 
studies reported that implanted stem cells do not differentiate into cardiac cells and that 
beneficial tissue regeneration that was reported previously can in all likelihood be 
attributed to paracrine signaling from the stem cells.208-219  In fact, some studies suggest 
that paracrine signaling from stem cells functions through cardioprotective signaling (to 
improve inotropy, reduce reactive oxygen species formation and limit apoptosis by 
activating pro-survival signaling) rather than/in addition to reparative signaling.220-222  In 
2010, Lai et al. reported that exosomes are directly involved this component of stem cell 
therapy.197,198  Arslan and colleagues corroborated these findings, reporting an infarct 
limiting effect of mesenchymal stem cell exosomes.199  The cardioprotective capacity of 
stem cell derived exosomes continues to receive considerable attention.223-225 
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What evidence suggests that remote preconditioning can elicit cardioprotection 
via exosomes in the absence of stem cell therapy?  In other words, does tissue that is 
typically subjected to ischemic conditioning (myocardium, skeletal muscle) secrete 
exosomes with cardioprotective qualities?  Two lines of evidence support this concept.  
First, exosomes from non-stem cells have been implicated in communicating survival 
signals between cells.  For example, Guitart et al. reported that exosomes from 
astrocytes are involved in conferring resistance against oxidative stress in cultured 
neurons,226 while Song et al. illustrated that exosomes from cancer cells prevent 
monocyte apoptosis by activating the MAPK signaling cascade.227  These same survival 
mechanisms are activated by remote preconditioning to prevent cardiomyocyte 
apoptosis. Importantly, cardiomyocytes have been shown to accept information from 
non-stem cell exosomes which mediate hypertrophy resistance following MI.228  
Second, hypoxia and ischemia (i.e. ischemic preconditioning stimulus) promote 
exosome secretion and modify exosome cargo, such as miRNA-30a229, TNF-α230, 
HSP20231, HSP60232.  Yamaguchi et al. reported that levels of insulin-like growth factor-
1 and miR-29a in exosomes was increased by chronic remote preconditioning and may 
be involved with improved functional recovery and wound healing following MI.233  Eldh 
et al. reported that exosomes secreted from mast cells subjected to an oxidative 
challenge are able to promote resistance against oxidative stress in target cells.234  
However, and in contrast, Li et al. found that miR-144 – a cardioprotective factor – was 
increased in the exosome-free (rather than exosome-rich) fraction of plasma following 
remote preconditioning, refuting the exosome theory.235  
4.2 Exosomes in Remote Preconditioning 
As discussed in the previous chapter, discovering the circulatory component 
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contributing to remote preconditioning, remains an important step in harnessing its 
cardioprotective power.  In 2014, Giricz et al. reported that exosomes are necessary 
and sufficient for cardioprotection by remote preconditioning.200  In this study, coronary 
perfusate was collected from ex vivo donor hearts after an ischemic conditioning 
protocol (3X 5-min episodes of global ischemia, interrupted by 5 min reperfusion).  
Recipient hearts were then pretreated for 30 min with donor coronary perfusate, or 
donor perfusate following exosome depletion (achieved by centrifugation), and 
subjected to a prolonged, 30 min period of sustained global ischemia.  Pre-ischemic 
transfer of conditioned coronary perfusate was cardioprotective (i.e., reduced infarct 
size in the acceptor hearts when compared with controls); however, depletion of 
exosomes from the perfusate eliminated efficacy.  These results strongly suggest that 
exosomes are requisite for remote preconditioning mediated cardioprotection against 
ischemia/reperfusion injury.  
A limitation of the Giricz study is that no direct evidence was provided to show 
that the ischemic preconditioning stimulus causes the release of exosomes into the 
circulation.  This issue was addressed in a subsequent protocol by Vicencio and 
colleagues who reported that remote preconditioning causes an increase in circulating 
exosomes, but, interestingly, concluded that exosomes per se provided protection 
regardless of whether a remote preconditioning stimulus had been applied.236  
5. Summary and Future Directions 
Interest in exosomes has surged in recent years, reflecting their seemingly 
ubiquitous role in biology and their potential in medical application.  Exosomes have 
been implicated remote preconditioning and, although supporting evidence is limited 
and disputed, they may provide mechanistic insight into the humoral component of 
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cardioprotection. 
The quest to identify the cardioprotective signal released by remote 
preconditioning is ongoing.  Exploratory and functional studies have generated many 
candidates, but, to date, no unifying theme for the communication component of remote 
ischemic conditioning has been developed.  Involvement of exosomes in humoral 
communication of remote preconditioning may facilitate the effort to elucidate the 
identity of the protective factors and promote successful clinical application.  
Theoretically, exosomes are ideal for protecting and transferring remote preconditioning 
signals between tissues.  The first step is to verify the involvement of exosomes; future 
studies can focus on harnessing the therapeutic potential of exosomes. 
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CHAPTER 3: STUDY OVERVIEW 
As discussed in Chapter 1, the prevalence of type-2 diabetes is increasing 
rapidly on a global scale.  The diabetic population is especially susceptible to 
myocardial infarction and, despite significantly improved survival following a coronary 
event, the resulting morbidity and mortality remains unacceptably high.  It is clear that 
type-2 diabetic patients are particularly dependent on development of novel 
cardioprotective strategies to treat AMI, and improve clinical outcome.  Despite clinical 
appeal and promising experimental success, ischemic conditioning, a leading strategy 
for cardioprotection, appears to be ineffective in multiple comorbid states. 
Remote preconditioning has had encouraging preclinical results, consistently 
showing potent infarct-sparing effects in many animal models, between species and in 
multiple tissues.  Efficacy in human trials is less convincing however, which has 
impaired translation to clinical application – a fate consistent with every previous 
cardioprotective candidate.  Nonetheless, preclinical success and compelling clinical 
advantages have prompted the effort to advance our understanding of remote 
preconditioning and strive to improve efficacy in the clinical setting.  We argue that 
addressing two fundamental issues will help to facilitate translation of remote 
preconditioning; (I) evaluating the impact of comorbidities on therapeutic efficacy and 
(II) characterizing the mechanism that communicates protection across a spatial barrier. 
Given this background, my dissertation will address three objectives. 
Objective 1: Evaluate the Efficacy of Remote Preconditioning in Type-2 Diabetes 
As reviewed in Chapter 1, there is evidence that the efficacy of ischemic 
preconditioning and postconditioning is either attenuated or eliminated in animal models 
of type-2 diabetes.  However, no studies to date have assessed whether the 
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cardioprotective effect of remote conditioning is lost or maintained in type-2 diabetic 
cohorts.  Accordingly, the primary aim of this study was to evaluate the efficacy of 
remote preconditioning in the well-established Zucker rat model of type-2 diabetes. 
Our goal was to focus on endpoints that have translational relevance.  The 
priority was the measurement of infarct size, the primary determinant of clinical outcome 
following AMI and the traditional standard for quantifying cardioprotection. 
Hyperglycemia is a fundamental characteristic of diabetes, and although its effect on 
cardioprotection is debated, evidence suggests that it plays a role in the suppression of 
ischemic conditioning.  We measured blood glucose to assess the effect of 
hyperglycemia on cardioprotection by remote preconditioning.  Importantly, we utilized a 
model of early-stage diabetes to target moderate hyperglycemia – rather than the 
supra-clinical hyperglycemia often seen with the later stages in rodent models of 
diabetes.  We hypothesize that Remote Preconditioning is Ineffective in Early-stage 
Type-2 Diabetes In Vivo (see Chapter 4). 
Objective 2: Investigate the Role of Exosomes in Remote Preconditioning  
As reviewed in Chapter 1, remote preconditioning transmits protection across a 
spatial barrier, with humoral signaling implicated in at least some models to play a role.  
Exosomes are extracellular particles found in the circulation which contribute to cell-to-
cell communication.  Although evidence is limited, these extracellular vesicles have 
been proposed to play a role in the humoral component of remote preconditioning.  Our 
second objective was to investigate the role of exosomes in remote preconditioning by 
treating cultured cardiomyocytes with exosomes collected in vivo from ischemic 
conditioned serum.  We hypothesized that Exosomes Serve as a Transport Mechanism 
of Protection in Remote Preconditioning (see Chapters 5 and 6). 
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Objective 3: Characterize the Defect in Remote Preconditioning Caused by Type-2 
Diabetes 
The final objective was to investigate the basis of the loss in cardioprotection 
associated with type-2 diabetes.  The majority of studies have focused on the effect 
type-2 diabetes has on signaling cascades and end-effectors in cardiomyocytes, which 
may desensitize the myocardium to ischemic conditioning.  Less understood is the 
effect of diabetes on the humoral component of protective signaling in remote 
preconditioning.  Our final objective was to evaluate the consequences of type-2 
diabetes on the humoral component (serum and circulatory exosomes) of remote 
preconditioning in rats.  We hypothesized that Type-2 Diabetes Inhibits Remote 
Preconditioning by Causing a Defect in Protective Signaling through the Serum and 
Exosomes (see Chapter 6). 
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CHAPTER 4: HYPOTHESIS 1: REMOTE PRECONDITIONING IS INEFFECTIVE IN 
EARLY-STAGE TYPE-2 DIABETES IN VIVO 
1. Rationale 
Emerging evidence indicates that type-2 diabetes affects infarct size, a primary 
metric for AMI injury, potentially by (I) preventing cardioprotection from ischemic 
conditioning and/or (II) increasing the sensitivity of the myocardium to ischemia-
reperfusion.  While preclinical investigations have reported resistance to ischemic 
preconditioning and postconditioning in the setting of diabetes, evidence of the effect of 
type-2 diabetes on remote preconditioning is limited.  Pre- and postconditioning have 
significant mechanistic overlap with remote conditioning (i.e. receptor-ligand 
interactions, intracellular survival kinase cascades and end-effectors: see Chapter 2) 
which suggests that remote conditioning may, similarly, be compromised in the setting 
of diabetes. 
Accordingly, we hypothesize that the efficacy of infarct size reduction with remote 
preconditioning is reduced or eliminated in type-2 diabetes.  Additionally, we 
hypothesize that type-2 diabetes sensitizes the myocardium to ischemia/reperfusion, 
resulting in larger infarct sizes when compared with normoglycemic controls.  We 
investigated our hypothesis using an in vivo model of acute myocardial ischemia and 
reperfusion in a translationally relevant model of diabetes.  
2. Materials 
Male Zucker rats were purchased from Harlan Laboratories, Inc. (Indianapolis, IN). 
Unisperse blue pigment was a generous gift from Ciba Geigy Corp. (Hawthorne, NY).  
We used an Accu-Chek Aviva blood glucose meter and test strips from Roche 
Diagnostics (Indianapolis, IN), and 5-0 proline (12 inch with curved needle) and spooled 
3-0 silk suture from Ethicon (Somerville, NJ).  Triphenyltetrazolium chloride, syringe 
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filters (0.2µm), neutral buffered formalin (10%) and saline (0.9% NaCl) were purchased 
from Fisher Scientific International, Inc. (Pittsburgh, PA). 
3. Methods 
This study, including subsequent chapters that use animal protocols, was 
approved by the Institutional Animal Care and Use Committee of Wayne State 
University and strictly abided by the Guide for the Care and Use of Laboratory Animals 
from the Institute of Laboratory Animals Resources (NIH Publication Vol. 25 No. 28, 
revised 1996). 
3.1 Zucker Rat Model of Type-2 Diabetes 
The Zucker Diabetic Fatty (ZDF-Leprfa/Crl) rat is a genetic model of type-2 
diabetes, which is the most common form of the disease in humans.  The Zucker 
Diabetic Fatty rat was derived through selective inbreeding for hyperglycemia in the 
Zucker Fatty (fa/fa) rat237, a strain with a mild diabetic phenotype caused by a missense 
mutation in the leptin receptor gene.238  This homozygous mutation causes a 
predictable and gradual development of severe diabetes, characterized by progressive 
development of insulin resistance, hyperglycemia, obesity and hyperlipidemia.  For 
clinical relevance, we have targeted the early stages of the progression to overt 
diabetes by using male rats between 10-12 weeks of age.  Enrollment was limited to 
males, as female Zucker Fatty rats are not likely to develop hyperglycemia unless fed a 
high-fat diet.237,239,240  In contrast, age-matched Zucker Lean rats (the genetic control 
strain) are homozygous or heterozygous for the wild-type gene, and are phenotypically 
normoglycemic and non-obese.238  All animals were housed at room temperature on a 
12-hour light/dark cycle and fed tap water and regular rodent chow, ad libitum.  
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3.2 In Vivo Model of Acute Myocardial Infarctin: Ischemia/Reperfusion 
Zucker Diabetic Fatty rats and age matched normoglycemic Zucker Lean rats 
were subjected to left coronary artery occlusion and reperfusion using methods routinely 
employed by our laboratory and by others.  Briefly: animals were anesthetized with 
pentobarbital sodium (40 mg/kg intraperitoneal, supplemented as required to maintain a 
deep surgical plane of anesthesia [on the order of 10 mg/kg/hour]).  Rats were 
positioned on a temperature-controlled heating pad, a tracheostomy was performed and 
the lungs were ventilated with room air.  The heart was exposed via a thoracotomy in 
the fourth intercostal space to expose the basal region of the heart, and the left 
coronary artery was ensnared by taking an intramyocardial stitch with a C-1 taper 
needle and 5-0 polypropylene suture from the atrioventricular groove to the region of the 
pulmonary cone.  Additional sutures were tied to each arm of the stitch suture to 
facilitate later release of the occlusion knot.241,242 
Myocardial ischemia was induced by tying a knot in the occlusion suture and 
maintained for 45 minutes, and was verified by tissue pallor, changes in the ECG 
tracing and arrhythmia.  Reperfusion was initiated by pulling on the release sutures and 
verified by the return of tissue blush.  Blood glucose concentration was measured 
immediately before the onset of coronary occlusion using the Accu-Chek monitor and 
test strips. 
3.3 Remote Preconditioning Treatment Groups 
Zucker Lean and Zucker Diabetic Fatty rats were randomly allocated into two 
treatment groups; sham operated controls and remote preconditioned.  All animals 
underwent bilateral femoral artery dissection and isolation.  This was followed by a 40-
minute intervention period, during which rats underwent either; (1) Remote 
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preconditioning: animals were subjected to 4-5 minute cycles of bilateral femoral artery 
occlusion, interspersed with 5 minutes reperfusion, followed immediately by coronary 
occlusion, seen in Figure 4–1; or (2) A time-matched, 40-minute control period with no 
femoral occlusion, followed by coronary occlusion, Figure 4–1.  
  
 
3.4 Tissue Processing and Imaging 
After 45 minutes of ischemia and 120 minutes of reperfusion, the occluding knot 
was re-tightened and an intravenous injection of 0.5 mL Unisperse Blue pigment was 
administered to delineate the area at risk (AR): i.e., the region of the heart distal to the 
occlusion and devoid of blue dye.  Subsequently, the heart was arrested in diastole (by 
intravenous injection of saturated KCL) and excised, sectioned transversely and the 
right ventricle removed.  Photographs were taken of the sections for later quantitation of 
AR.  Immediately thereafter, the sections were incubated in 2,3,5-triphenyltetrazolium 
chloride (TTC) for 15 minutes at 37°C, followed by photographic documentation.  Using 
this method, viable tissue is stained red while the necrosis remains unstained so 
appears pale, examples shown in Figure 4–2A.  Area at risk and infarct size were 
analyzed in a blinded manner using image analysis software (SigmaScan Pro SPSS 
Figure 4–1: Treatment schematic. Zucker Lean and Zucker Diabetic Fatty rats received sham
operation or remote preconditioning. The red box represents coronary artery occlusion, green
boxes represent bilateral femoral artery occlusion, the white box represents matched time with
no occlusions. Infarct size was assessed after 2 hours of coronary reperfusion. The arrow
denotes timing of the blood glucose measurement. 
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Inc., Chicago IL) and measurements were corrected for tissue weight.  Area at risk is 
reported as a % of the left ventricle and infarct size is reported as a % of the area at 
risk. 
3.5 Data and Statistic Analysis 
Data were analyzed with GraphPad Prism software (GraphPad Software, Inc, La 
Jolla, CA).  Endpoints were compared by student t-test (for 2-group comparisons) or 
one-way Analysis of Variance (ANOVA: for 4-group comparisons).  If significant F-
values were obtained by ANOVA, post-hoc pairwise comparisons between groups were 
made with the Newman-Keuls test.  Results are presented as means ± SEM.  For the 
cohorts that underwent remote preconditioning, linear regression was used to analyze 
the relationship between blood glucose and infarct size. 
4. Results 
4.1 Remote Preconditioning is ineffective in Early-stage Type-2 Diabetes 
Area at risk (the primary determinant of infarct size in the rat model) did not differ 
among groups: mean values were 20 ± 2%, 18 ± 2%, 23 ± 1%, and 19 ± 2% of the total 
LV weight in the Control-Lean, RIPC-Lean, Control-Fatty and RIPC-Fatty cohorts, 
respectively (Figure 4–2B). 
In untreated control animals, infarct size (i.e., area of necrosis, expressed as a % 
of the area at risk) was comparable in both strains, averaging 63 ± 6% in the Zucker 
Lean group and 60 ± 9% in diabetic Zucker Fatty rats.  As expected, in the Zucker Lean 
cohort, remote preconditioning was cardioprotective: infarct size was significantly 
smaller in the RIPC-Lean group when compared with the Lean-Controls (10 ± 3%* 
versus 63 ± 6%, respectively, *p<0.01 vs Lean Controls, see Figure 4–2c).  In contrast, 
remote preconditioning was ineffective in the diabetic strain: there was no difference in 
40 
 
infarct size between the RIPC-Fatty and the Control-Fatty groups (60 ± 9% vs 65 ± 4% 
respectively), Figure 4–2C.  
 
4.2 Hyperglycemia Alone Does Not Explain the Loss in Efficacy of Remote 
Preconditioning  
As expected, the pooled cohort of diabetic Zucker Fatty rats (including both 
Control and RIPC groups) was characterized by moderate but significantly elevated 
non-fasting blood glucose values when compared with the Zucker Lean rats (278 ± 15 
vs 150 ± 12 mg/dl, P<0.01); (Figure 4–3A).  To obtain insight into whether the loss in 
efficacy of remote preconditioning in Zucker diabetic rats was simply due to 
hyperglycemia, infarct size was plotted as a function of blood glucose concentration for 
Figure 4–2: Efficacy of remote preconditioning is lost in type-2 diabetes. A. Original
images of rat hearts from Zucker Lean and Zucker Fatty animals assigned to receive remote
ischemic preconditioning (RIPC) or no intervention (Control).  Hearts were cut into transverse
slices and stained with triphenyltetrazolium chloride; viable tissue stains red whereas necrotic
myocardium remains unstained and appears pale. B. Area at risk, expressed as a % of the total
LV weight (mean + SEM) C. Infarct size, expressed as a % of the risk region (mean + SEM).  *
P<0.01 vs. Lean-Control, N= 6-9/group. 
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all animals (both Zucker Fatty and Zucker Lean) treated with remote preconditioning 
(Figure 4–3B).  If this concept were true, one would expect that all data points would fall 
along a single regression line: i.e., rats with the highest blood glucose values would 
develop the largest infarcts.  This was not supported by the data; in rats treated with 
remote preconditioning, there was no association between blood glucose concentration 
and infarct size.  
 
 
5. Summary 
In summary, we report that, in this rat model of type-2 diabetes, there is no 
increase in the sensitivity of the myocardium to ischemia-reperfusion per se.  This is 
supported by the observation that infarct size was similar (not increased) in Control 
Zucker Fatty animals when compared with Control Zucker Lean animals.  Second, and 
most importantly, remote preconditioning is defective in the Zucker model of type-2 
diabetes, providing no protection against lethal ischemia/reperfusion injury in vivo.  This 
is demonstrated by our finding that, while remote preconditioning had the expected, 
potent infarct-sparing effect in Zucker Lean rats, this protective effect was absent in 
Figure 4–3: Failure of remote preconditioning to reduce infarct size in the diabetic
Zucker cohort is not associated with hyperglycemia. A. Blood glucose for Zucker Lean
and diabetic Zucker Fatty rats measured immediately before prolonged ischemia (mean +
SEM). B.  Infarct size plotted as a function of blood glucose concentration for all rats (Zucker
Lean and Zucker Fatty) treated with remote preconditioning. RIPC, remote preconditioning. 
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diabetic Zucker Fatty rats.  Finally, we report that the defect in remote preconditioning 
does not appear to be caused exclusively by hyperglycemia.  Our data support this 
conclusion, as we show no overall association between blood glucose concentration 
and infarct size in RIPC-treated rats. 
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CHAPTER 5: HYPOTHESIS 2: THE TRADITIONAL ULTRACENTRIFUGATION 
TECHNIQUE FOR EXOSOME ISOLATION IS INADEQUATE TO ISOLATE 
PROTECTIVE FACTOR(S) FROM REMOTE PRECONDITIONING 
1. Rationale 
As discussed in Chapter 3, protection from remote preconditioning is 
communicated from the site of the ischemic conditioning stimulus to the at-risk 
myocardium.  Convincing evidence indicates that a humoral factor(s) is, at least 
partially, involved with overcoming this spatial barrier; however the identity of the 
protective factor remains unknown.  
Exosomes are nano-sized extracellular vesicles involved with intracellular 
communication (see Chapter 2).  Exosomes have garnered recognition for their 
potential as a delivery system, providing protected and targeted transportation of both 
endogenous, exogenous243,244 and synthetic245 cargo.  Recent evidence has implicated 
exosomes as the carrier mechanism for the protective humoral factor(s) involved in 
remote preconditioning; Giricz et al. proposed that exosomes are required for the 
reduction of infarct size achieved by treating naïve hearts with coronary perfusate from 
preconditioned, buffer-perfused hearts.200  Vicencio et al. later reported that exosomes 
isolated from blood plasma are sufficient to elicit protection, regardless of whether 
samples were from sham or remote preconditioned subjects.236  It is clear that 
exosomes have the potential to participate in cardioprotective signaling; however their 
role in remote preconditioning remains poorly characterized.  Our objective was to 
investigate the mechanistic role of circulatory exosomes in remote preconditioning. 
We hypothesized that protection from remote preconditioning could be 
transferred to cultured cardiomyocytes through blood serum, a phenomenon described 
previously.53  Additionally, based on findings reported by Giricz et al., we hypothesized 
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that the protective component in serum is transported by exosomes.  We predicted that 
exosomes could be isolated from remote preconditioned serum and transported to 
cardiomyocytes to promote resistance against lethal hypoxia/reoxygenation injury.  To 
test our hypothesis, we measured the protective effect of remote preconditioned serum, 
exosome-rich serum and exosome-depleted serum, with the latter two fractions 
obtained using the traditional ultracentrifugation technique for isolating exosomes.  
2. Materials 
Cultured HL-1 cardiomyocytes were a generous gift from Dr. William Claycomb 
(Louisiana State University Health Science Center, New Orleans, LA). Claycomb 
medium, 0.05% trypsin/EDTA, fetal bovine serum (FBS), ascorbic acid, 
penicillin/streptomycin, L-glutamine, norepinephrine, gelatin, fibronectin, HEPES, 
sodium-lactate, sodium bicarbonate, KCL, and Krebs-Henseleit (KH) buffer were 
purchased from Sigma-Aldrich, Inc (St Louis, MO).  Sprague Dawley retired breeder 
rats were purchased from Harlan Laboratories Inc. (Indianapolis, IN). Mini-PROTEAN 
precast PAGE gels, sodium dodecyl sulfate (SDS), urea, dithiothreitol, Tris base, 
nitrocellulose membranes, Triton X-100 and Tween 20 were purchased from Bio-Rad 
Laboratories (Hercules, CA).  Primary and secondary antibodies used for immunoblot 
analysis were purchased from Cell Signaling Technology (Danvers, MA). 
3. Methods 
3.1 Culturing HL-1 Cardiomyocytes 
HL-1 cells are an immortalized mouse cardiomyocyte cell line, derived from a 
murine atrial tumor, that maintain their morphology and contractile function through 
repeated passaging.246  Cells were maintained at 37°C in 5% CO2 and 95% room air 
with ~95% humidity.  Claycomb culture medium, supplemented with 10% FBS, 
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penicillin/streptomycin (respectively, 100 U/ml; 100 μg/ml), L-glutamine (2mM final) and 
norepinephrine (0.01mM final) was replaced daily and cells were sub-cultured when 
they reached 100% confluency, as previously described.246  HL-1 cells were passaged 
as directed by the protocol (Multi Channel Systems, Reutlingen, Germany).  Briefly: 
flasks were washed twice with trypsin (0.05% with EDTA) and incubated with trypsin 
until cells were dislodged.  Cells were collected from the flask and washed with culture 
medium (contains trypsin inhibitor).  The cells were then pelleted by centrifugation at 
500xG for 5 minutes, resuspended in culture medium and re-plated in flasks pre-coated 
with gelatin/fibronectin.  
3.2 Hypoxia/Reoxygenation 
HL-1 cells grown in non-coated, tissue culture TC-treated 60 mm culture dishes, 
were subjected to 2.5 hours hypoxia and 20 hours of reoxygenation when they reached 
~90% confluency.  Hypoxia was established by replacing culture medium with hypoxia 
buffer (mM: 125 NaCl, 8 KCl, 1.2 KH2PO4, 1.25 MgSO4, 1.2 CaCl2, 6.25 NaHCO3, 20 
HEPES, 5.5 glucose, 20 2-deoxy-D-glucose, 5 Na-lactate; preheated to 37°C and 
adjusted to pH 6.6), sealing culture dishes in a hermetic chamber with GasPak EZ Gas 
Generating Sachets (GasPakTM EZ, BD Biosciences, San Jose, CA) and incubating 
the chamber at 37°C.  Cells were reoxygenated by removing dishes from the hypoxia 
chamber, replacing the hypoxia buffer with serum-free Claycomb media (preheated to 
37°C), and incubating per usual in room air at 37°C.  
3.3 Trypan Blue Cell Death Assay 
Twenty hours after hypoxia/reoxygenation, all HL-1 cells were collected, 
including adherent live and dead cells (by trypsinization) and non-adherent cells.  The 
cells were pelleted by centrifugation (500g for 5 minutes) and resuspended in 2 mL 
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Claycomb media to yield 2-3 million cells per mL).  The cell suspension was stained 
with 0.4% Trypan Blue dye (1:1 ratio of cell suspension:dye) to distinguish viable from 
dead cells.  Trypan blue dye is membrane impermeable and thus cannot penetrate 
viable cells with intact plasma membrane while, in contrast, dead and dying cells have 
damaged plasma membranes, allowing trypan blue to accumulate within the cell.  
Stained cell suspensions were visualized with phase contrast microscopy at 10x 
magnification (inverted microscope: Fisher Scientific, Pittsburgh, PA); viable and dead 
cells (appearing unstained and blue, respectively) were counted using a standard 
hemocytometer.  Percent cell death was calculated as: 
Cell death (%) = (dead cells / (dead cells + live cells)) x100 
3.4 Remote Preconditioning and Serum Collection 
The goal of the dissertation is to assess the exosome hypothesis of remote 
conditioning in Zucker Lean and diabetic Zucker Fatty rats.  However, as a first step 
(and as described in this Chapter), Sprague Dawley rats were used for preliminary 
studies to validate the protocol for serum transfer to HL-1 cells and proof-of-concept for 
exosome isolation and exosome transfer to HL-1 cells.  
Rats were anesthetized with pentobarbital sodium (40 mg/kg intraperitoneal), 
ventilated with room air and maintained on a temperature-controlled heating pad.  All 
animals underwent femoral artery isolation with blunt dissection as described in Chapter 
4, and were subsequently allocated into two treatment groups; remote preconditioned 
animals received brief repeated episodes of femoral artery occlusion (4x 5-minute 
ischemia and 5-minute reperfusion) and the sham-operated group received 40 minutes 
without femoral artery occlusion (see Figure 5–1).  Following remote preconditioning or 
the time-matched sham period, a thoracotomy was performed and 6-8 mL of blood was 
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rapidly collected from the left ventricle via cardiac puncture with an 18-guage needle.  
Blood was allowed to coagulate at room temperature for 20 minutes and serum was 
isolated by centrifugation at 2,000xG for 20 minutes at 4°C. 
 
3.5 Traditional Ultracentrifugation for Exosome Isolation from Serum 
Exosomes were isolated from serum using the traditional ultracentrifugation 
technique.194  First, serum was centrifuged at 20,000xG for 45 minutes to sediment cell 
Figure 5–1: Methods schematic for transferring protection from remote preconditioning
to HL-1 cardiomyocytes. A. Sprague Dawley rats underwent remote preconditioning or sham-
operation, followed by blood collection. B. Blood was processed by traditional ultracentrifugation
to obtain purified serum, exosome-depleted serum and an exosome-rich pellet. C. HL-1 cells
underwent normoxia or hypoxia. Hypoxic cells were treated with buffer (control), purified serum,
exosome-depleted serum or the exosome-rich-pellet resuspended in buffer, administered at 1
hour before the onset of hypoxia, re-administered at the onset of hypoxia (black arrows) and
maintained throughout 2.5 hours of hypoxia.  Cell death was measured 20 hours after
reoxygenation. Green boxes represent bilateral femoral artery occlusion. Blue boxes represent
sample treatments for HL-1 cells. White arrows denote centrifugation or filtration steps. RIPC,
remote preconditioning. 
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debris and contaminants.  Next, 2 mL of purified serum was filtered through a 0.2µm 
syringe filter to remove larger extracellular vesicles and protein aggregates, while the 
remaining serum was aliquoted into storage tubes.  The filtered serum was then 
centrifuged at 120,000xG for 2 hours, yielding a presumably exosome-rich pellet and 
exosome-depleted supernatant.  The pellet was resuspended in 2 mL (equivalent to the 
starting volume of serum) of 1x Krebs Henseleit buffer.  During exosome isolation, all 
samples were kept at 4°C or on ice.  The same ultracentrifuge, ultracentrifuge tubes 
(ThermoFisher Scientific, Pittsburgh) and rotor (fixed angle S110AT-0019: Hitachi Koki 
Co., Takeda, Hitachiaka City) were used for the preparation of all samples, and the 
sample volume (2 mL) was kept constant (see Figure 5–1). 
3.6 Serum and Exosome Transfer: Treating HL-1 Cardiomyocytes 
HL-1 cells were treated with purified serum, the resuspended pellet and 
exosome-depleted serum isolated by traditional exosome isolation.  Treatment was 
initiated at 1 hour before the onset of hypoxia by replacing the medium in each culture 
dish with 3 mL of fresh Claycomb medium supplemented with purified serum or serum 
fractions (see treatment details below).  Treatment was continued during hypoxia by 
replacing the Claycomb medium with 3 ml hypoxia buffer again supplemented with 
purified serum or serum fractions. 
3.7 HL-1 Cardiomyocyte Treatment Groups 
To establish the model and optimize the dose, HL-1 cells were initially treated 
with 0%, 1%, 2%, 4% and 8% serum/medium, by volume.  In these preliminary 
experiments, we found comparable results (attenuation of HL-1 cell death) with 4% and 
8% serum/medium (data not shown).  Accordingly, in subsequent serum transfer 
experiments, the lowest effective dose, 4% serum/medium, was applied.  In exosome 
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transfer experiments, HL-1 cells were treated with either 100µL buffer alone (control), 
100µL exosome-depleted supernatant, or 10µL, 50µL or 100µL of the presumably 
exosome-rich (resuspended pellet) sample. 
3.8 Gel Electrophoresis Immunoblotting 
To confirm the presence of HSP60232 (an exosome marker) in the exosome-rich 
pellet, samples were probed by standard immunoblotting.  Samples were prepared with 
lysis buffer (8M urea, 5mM dithiothreitol, 2% SDS and 25mM Tris Cl, pH 8) and 
incubated for 30 minutes at room temperature, then treated with Lamelli buffer (without 
heating).  Samples were resolved on 4-15% gradient gels at 15-50 µg/well and protein 
was transferred from gel to nitrocellulose membrane.  The membranes were blocked 
with 5% nonfat milk in 0.1% Tween 20 Tris-buffered saline (TTBS) for 1 hour at room 
temperature and probed overnight at 4°C with primary antibody (diluted 1:1000 in 5% 
milk in TTBS).  Horseradish peroxidase-conjugated secondary antibodies (1:10,000 in 
5% milk in TTBS) were incubated for 1 hour at room temperature and immunoreactive 
proteins were visualized by adding enhanced chemiluminescence substrate and 
exposure to X-ray film (ThermoFisher Scientific, Pittsburgh, PA) 
3.9 Statistical Analysis 
Data were analyzed with GraphPad Prism software, GraphPad, Inc. (La Jolla, 
CA).  Endpoints were compared among groups by one-way ANOVA.  If significant F-
values were obtained by ANOVA, Tukey’s multiple comparisons test was used for 
subsequent pairwise comparisons or Dunnett’s multiple comparison test was used to 
compare treated groups to control.  Results are reported as means ± SEM.  
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4. Results 
4.1 Serum from Remote Preconditioned Sprague Dawley Rats Protects HL-1 
Cardiomyocytes from Hypoxia/Reoxygenation 
As expected, in HL-1 cardiomyocytes treated with buffer, hypoxia/reoxygenation 
caused significant cell death when compared with the normoxic controls: 45±1% versus 
10±2% of the total cell count, respectively (*p<0.001 vs Normoxia, see Figure 5–2A).  
Treatment with serum from remote preconditioned animals reduced cell death to 31 ± 
2% (*p<0.05 vs Buffer-treated, see Figure 5–2A).  However, treatment with serum from 
sham-operated Sprague Dawley rats did not have a significant effect on cell death in 
HL-1 cells subjected to hypoxia/reoxygenation (Figure 5–2B). 
 
 
 
 
 
   
Figure 5–2: HL-1 cells are protected by treatment with remote preconditioned serum.  Cell
death was assayed with trypan blue and reported as a % of the total cell count. RIPC, remote
preconditioning. n=5/group, *p<0.05 versus Buffer-treated, **p<0.001 versus Normoxia. 
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4.2 Treating HL-1 Cells by Exosome Transfer: Traditional Ultracentrifugation Isolation 
The traditional ultracentrifugation technique (100,000xG for 2 hours) fractionated 
serum into two phases, a pellet and a supernatant.  The pellet contained exosome 
markers, demonstrated by qualitative immunoreactivity for HSP-60 (Figure 5–3).  In 
apparent contrast to our hypothesis, HL-1 cell death caused by hypoxia/reoxygenation 
was not significantly changed by treatment with 10µL, 50µL, 100µL of resuspended 
pellet (presumably exosome-rich, EXO: 37 ± 5%, 38 ± 6%, 39 ± 5% cell death, 
respectively) compared with the buffer-treated control group (39 ± 5% cell death, see 
Figure 5–3).  Rather, cell death was significantly reduced by treatment with the 
supernatant (presumably exosome-depleted; p<0.05 vs KH buffer treated, p<0.05 vs 
EXO treated groups, see Figure 5–3). 
Figure 5–3: HL-1 cells are protected by the supernatant from the traditional 
ultracentrifugation technique.  A. Immunoreactivity for HSP-60 in pellets obtained from 
individual serum samples. B. HL-1 cells were treated with varying doses of exosome-rich 
sample or supernatant. Cell death was assayed with trypan blue and reported as a % of the 
total cell count. n=5/group. 
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5. Summary 
In summary, we report that the protection from remote preconditioning can be 
transferred through the serum and render cultured HL-1 cardiomyocytes resistant to 
hypoxia/reoxygenation.  This is supported by the observation that treatment with serum 
collected from remote preconditioned Sprague Dawley rats reduced HL-1 cell death 
caused by hypoxia/reoxygenation, while serum from non-remote preconditioned rats did 
not protect cells.  Secondly, we found that the traditional ultracentrifugation isolation of 
exosomes fractionates serum into a supernatant and an exosome rich pellet, 
demonstrated by immunoreactivity for exosome markers.  However, and contrary to our 
hypothesis, we report that protection from remote preconditioning was not transferred in 
the presumably exosomes-rich pellet that was isolated by the traditional 
ultracentrifugation technique.  Rather, we found that protection was transferred by the 
presumably exosome-depleted supernatant.  This conclusion is supported by our 
observation that treatment with the pellet sample did not affect HL-1 cell death caused 
by hypoxia/reoxygenation, while the supernatant significantly reduced cell death. 
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CHAPTER 6: HYPOTHESIS 3: ENHANCED ULTRACENTRIFUGATION TECHNIQUE 
FOR EXOSOME ISOLATION SEQUESTERS A PROTECTIVE FRACTION OF SERUM 
1. Rationale 
In Chapter 5, we investigated the role of exosomes in the humoral component of 
remote preconditioning.  Contrary to our hypothesis (and a previous report200), we found 
that the exosome-rich pellet isolated with the traditional centrifugation technique did not 
transmit protection to HL-1 cardiomyocytes.  Instead, the exosome-depleted serum 
rendered cells resistant to hypoxia/reoxygenation (See Figure 5–3). These results may 
be interpreted as evidence that; 1) exosomes do not transmit the protective factor(s) 
from remote preconditioning.  Alternatively, it is possible that 2) exosomes do transmit 
protection, however the traditional ultracentrifugation isolation technique is insufficient to 
adequately isolate exosomes, resulting in a supernatant that contains the protective 
exosomes. 
Ultracentrifugation isolation of exosomes is ultimately a method of differential 
centrifugation, which isolates particles/structures at different rates, depending on 
physical attributes of the solute (diameter, density) and the solution (viscosity).  
Theoretically, as a particle with finite characteristics, exosomes can be specifically 
sedimented from a solution.  In Chapter 5, exosomes were isolated using the traditional 
ultracentrifugation technique, the most commonly used method for isolating exosomes.  
It is becoming clear, however, that this protocol is inefficient, achieving partial exosome 
sedimentation.19,247,248  This may be particularly problematic for viscous solutions, such 
as serum.  To accurately test our hypothesis that exosomes are responsible for 
transmitting protective signals, the isolation technique must produce a high yield, 
exosome-rich sample and an exosome-depleted sample.  Our objective was to enhance 
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the ultracentrifugation procedure in order to augment sedimentation and improve 
depletion of exosomes in the serum.  Accordingly, we aimed to enhance the 
ultracentrifugation technique by sequentially increasing the centrifugation force in an 
effort to increase the exosome yield and improve the depletion of exosomes from the 
serum.  First, we hypothesized that sequentially increasing ultracentrifugation force 
would reveal the optimal ultracentrifugation protocol, i.e. improved exosome 
sedimentation.  Second, we hypothesized that the exosome-rich samples isolated with 
the enhanced ultracentrifugation technique would confer the protection of remote 
preconditioning, whereas exosome-depleted serum will not protect cells. 
2. Materials 
Refer to Chapter 5, section 2. 
3. Methods 
3.1 Culturing H-1 Cardiomyocytes  
Refer to Chapter 5, section 3.1. 
3.2 Hypoxia/Reoxygenation 
Refer to Chapter 5, section 3.2 
3.3 Trypan Blue Cell Death Assay 
Refer to Chapter 5, section 3.3 
3.4 Remote Preconditioning and Serum Collection 
Refer to Chapter 5, section 3.4 
3.5 Sequential Ultracentrifugation to Maximize Exosome Isolation  
Evidence suggests that sedimentation of exosomes with the traditional 
ultracentrifugation technique (used in Chapter 5) is not efficient.247  To identify a 
protocol that maximizes exosome sedimentation, we sequentially increased the radial 
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force of ultracentrifugation and monitored exosome-marker content.  Serum was 
collected from Sprague Dawley rats and filter purified as described in Chapter 4.  Serum 
was then centrifuged, beginning with the traditional exosome isolation force 
(100,000xG), and increased stepwise by 50,000xG increments.  The pellet was 
collected after each step and resuspended in 1x Krebs Henseleit (KH) buffer.  After the 
terminal spin at 300,000xG, the pellet and supernatant were collected for exosome 
analysis.  All spin cycles were 2 hours, except the last step, which lasted 12 hours.  See 
Figure 6–1A for protocol. 
 
3.6 Enhanced Ultracentrifugation Isolation of Exosomes from Serum 
Based on results obtained with sequential ultracentrifugation, an enhanced 
ultracentrifugation protocol was established; for optimal exosome sedimentation, filtered 
serum was centrifuged at 300,000xG for 12 hours.  This robust isolation protocol 
fractionated the serum into a pellet and a biphasic supernatant, a top phase and bottom 
Figure 6–1: Sequential
ultracentrifugation for isolation of
exosomes from serum. A. Protocol 
schematic for sequential
ultracentrifugation. The box denotes the
traditional ultracentrifugation force. B.
Immunoblotting was used to detect
exosome markers in the pellet from each
step and the supernatant from the
terminal step. C. Sypro Ruby gel stain 
was used to detect protein content in
each lane. 
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phase (see Figure 6–2B).  The pellet was resuspended in 2 mL (equivalent to the 
starting volume of serum) of 1x KH buffer.  After initial coagulation of blood at room 
temperature for serum collection, all samples were kept at 4°C or on ice. 
 
3.7 Sample Transfer and HL-1 Cardiomyocyte Treatment Groups 
The HL-1 cell treatment technique was the same as described in Chapter 5 
section 3.7, and the treatment regimen is depicted in Figure 6–2.  HL-1 cells were 
treated with buffer, whole unfractionated serum (4%, as in Chapter 5) or fractions of 
serum harvested after the enhanced exosome isolation protocol (described below).  For 
all serum fractions, the treatment volumes were adjusted using KH buffer to match the 
Figure 6–2: Protocol schematic for transferring fractionated serum to HL-1
cardiomyocytes. A. Sprague Dawley rats underwent sham-operation or remote
preconditioning, followed by blood collection. Green boxes represent bilateral femoral artery
occlusion.  B. Blood is processed by the enhanced ultracentrifugation isolation technique to
obtain samples to treat HL-1 cells; purified serum, pellet, top and bottom phases of the
supernatant. White arrows denote centrifugation or filtration steps.  C. HL-1 cells were subjected
to normoxia or hypoxia/reoxygenation. Cells were untreated or treated with buffer (buffer) or
processed blood samples (3.5 hour treatment beginning 1 hour prior to hypoxia). Cell death was
measured 20 hours after reoxygenation. Blue boxes represent sample treatments for HL-1 cells.
Black arrows denote administration of buffer, serum or serum fractions. RIPC, remote
preconditioning. 
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volume of unfractionated serum applied to the cells. 
3.8 Detecting Exosome Markers and Total Protein 
Each successive pellet from the sequential ultracentrifugation protocol was 
resuspended in 0.5 mL KH buffer, 25% of the starting volume, to facilitate exosome-
marker detection.  The pellet isolated by the last step (300,000xG) was highly 
concentrated and, thus, was diluted in 4 mL KH buffer (two-fold dilution from the starting 
volume of serum) to prevent overloading the gel.  Exosome content was evaluated as 
described in Chapter 5 Section 3.6, by separating proteins by SDS-PAGE, transferring 
proteins to nitrocellulose membranes and immunoblotting for exosome markers 
(HSP60,232 flotillin-1188 and GAPDH249).  Our objective was to qualitatively determine the 
exosome content of the samples to assess the efficacy of each sequential 
ultracentrifugation step.  As such, we were interested in the presence/absence and 
relative concentration of exosomes rather than the ratio of exosomes to protein, so 
samples were loaded into gel wells in equal volumes, regardless of protein 
concentration.  Total protein separation was visualized with SYPRO Ruby stain on a 
separate gel, as per the manufacturer’s instructions (Invitrogen).  Briefly, the SDS-
acrylamide gel was fixed (50% methanol, 7% acetic acid) for 30 minutes, stained 
overnight with SYPRO Ruby and washed (10% methanol, 7% acetic acid) for 1 hour.  
Red fluorescence was photographed with a VersaDoc MP 4000 imaging system (Bio-
Rad, Hercules, CA).  Immunoblots and protein stain images were converted to gray 
scale. 
3.9 Statistical Analysis 
Data were analyzed with GraphPad Prism software, GraphPad, Inc. (La Jolla, 
CA).  Data are presented as means ± SEM. Endpoints were compared among groups 
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by one-way ANOVA as appropriate.  If significant F-values were obtained by ANOVA, 
Dunnett’s multiple comparisons test was used to compare treated groups to control.  
4. Results 
4.1 Sequential Ultracentrifugation and the Enhanced Protocol Maximize Exosome 
Sedimentation 
Exosomes were detected in the pellet after every ultracentrifugation step by 
immunoblotting for HSP60, flotillin-1 and GAPDH (Figure 6–1B).  The supernatant 
collected after the last step of ultracentrifugation (300,000xG for 12 hours) did not 
contain exosomes markers (see Figure 6–1B).  Protein content of the pellet was 
proportional to the ultracentrifugation force, with the highest content in the pellet 
collected after the 300,000xG step.  
The simplified protocol for enhanced ultracentrifugation isolation of exosomes 
(300,000xG for 12 hours) separated serum into three fractions; the pellet, the bottom 
Figure 6–3: Exosome content and HL-1 cell death following treatment with serum or
serum fractions isolated by enhanced ultracentrifugation. A, B. Exosome content was
qualitatively assayed by immunoblotting for exosome markers. C. Cell death was assayed with
trypan blue to assess viability in each treatment condition. Cell death is reported as a % of the
total cell count. RIPC, remote preconditioning. n=5/group, *P=<0.01. 
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phase of the supernatant (directly adjacent to the pellet, containing exosome markers) 
and the top phase of the supernatant (devoid of exosome makers, as detected by 
qualitative immunoblotting analysis; see Figure 6 – 3A). 
4.2 Treating HL-1 Cells with Samples from the Enhanced Ultracentrifugation Technique 
Percent HL-1 cell death was not significantly changed by treatment with either 
the resuspended pellet (51 ± 4%) or and top fraction of the supernatant (52 ± 10%) 
when compared to buffer treatment (45 ± 1%; Figure 6 – 3B).  In contrast, treatment 
with the bottom fraction of the supernatant reduced HL-1 cell death when compared 
with buffer treatment: 29 ± 2% vs 45 ± 1, respectively (p<0.01, see Figure 6 – 3B). 
5. Summary 
In summary, we report that the traditional ultracentrifugation technique does not 
efficiently sediment exosomes from serum, resulting in a partial isolation of exosomes 
and residual exosomes in the supernatant.  These conclusions are supported by 
qualitative immunoblot analysis detecting exosome markers in pellets formed by 
ultracentrifugation forces exceeding the traditional ultracentrifugation protocol (up to 
300,000xG).  We report that ultracentrifugation at 300,000xG for 12 hours fractionates 
serum into three distinct phases; the pellet (as expected, expressing exosome markers), 
the bottom phase of the supernatant (which was also enriched with exosome markers) 
and the top phase of the supernatant (which is depleted of exosome markers).  Finally, 
we report that exosomes may play a role the humoral component of remote 
preconditioning, however they are not sufficient for protection.  This is illustrated by the 
reduction in cell death from hypoxia/reoxygenation by treatment with the exosome 
marker-rich bottom phase, but not the exosome marker-rich pellet.  
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CHAPTER 7: HYPOTHESIS 4: THE HUMORAL COMPONENT OF REMOTE 
PRECONDITIONING IS DEFECTIVE IN TYPE-2 DIABETES 
1. Rationale 
As reported in Chapter 4, we have provided the first evidence that, in agreement 
with our hypothesis, remote preconditioning does not reduce infarct size in the Zucker 
rat model of type-2 diabetes.  These results are consistent with previous studies 
reporting that protection with ischemic preconditioning and postconditioning is 
attenuated or lost in the setting of diabetes; however the mechanism of this dysfunction 
remains unclear.  
The majority of previous studies have focused on the concept that the diabetic 
myocardium becomes refractory to protection from ischemic conditioning, potentially as 
a result of changes in protein expression, activity of signaling cascades and/or 
activation of end effectors in cardiomyocytes.100,108,110-112,250-256  In the setting of remote 
conditioning, there is a possible alternative explanation for the failed protection: as 
discussed in Chapter 1, Jensen et al. investigated the humoral component of remote 
preconditioning in diabetes, rather than the effect of diabetes on the myocardium.  This 
study reported that plasma collected from diabetic patients subjected to a remote 
preconditioning stimulus was protective (i.e. reduced infarct size when administered to 
buffer-perfused rabbit hearts), while plasma from diabetic volunteers with peripheral 
neuropathy did not maintain this protective capacity.124  The objective of this chapter is 
to pursue this concept and assess the effect of type-2 diabetes on the humoral 
component of remote preconditioning. 
We hypothesize that diabetes causes a defect in the humoral signaling of remote 
preconditioning, which prevents transfer of protection.  We tested our hypothesis with 
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an in vitro analysis of the protective efficacy of serum and serum fractions harvested 
from hyperglycemic Zucker Fatty and normoglycemic Zucker Lean rats and isolated 
using our enhanced ultracentrifugation technique described in Chapter 6. HL-1 
cardiomyocytes were treated with serum and serum fractions from remote 
preconditioned rats from both strains and subjected to hypoxia/reoxygenation.  As in our 
previous experiments, the primary endpoint was HL-1 cell viability following 
reoxygenation.  We proposed that serum and supernatant-bottom fractions obtained 
from Zucker Lean rats subjected to remote conditioning will provide protection against 
hypoxia/reoxygenation, while samples from Zucker Fatty rats will not reduce cell death.  
We also predict that the supernatant-top fraction will not affect cell death caused by 
hypoxia/reoxygenation in either Zucker cohort. 
2. Materials 
See Materials sections from Chapter 4 and 5.  
3. Methods 
3.1 Culturing HL-1 Cardiomyocytes 
Refer to Chapter 5, section 3.1. 
3.2 Hypoxia/Reoxgenation 
Refer to Chapter 5, section 3.2 
3.3 Trypan Blue Cell Death Assay 
Refer to Chapter 5, section 3.3 
3.4 Serum and Exosome Transfer: Treating HL-1 Cardiomyocytes 
In Chapter 5 and Chapter 6, Sprague Dawley rats were used in preliminary 
studies to validate the protocol for serum transfer to HL-1 cells and proof-of-concept for 
exosome isolation and exosome transfer to HL-1 cells.  Here we addressed our primary 
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objective; we assess the hypothesized role of exosomes in the humoral transfer of 
protection in remote preconditioning in the setting of type-2 diabetes. 
Zucker Fatty rats were used as a model of early-stage type-2 diabetes, as 
introduced in Chapter 4, while Zucker Lean rats served as the normoglycemic control 
strain.  Remote preconditioning, blood collection and processing, exosome isolation and
 
Figure 7–1: Methods schematic for transferring protection from remote preconditioning
to HL-1 cardiomyocytes in the setting of type-2 diabetes. A. Zucker Lean and Zucker
Fatty rats underwent remote preconditioning followed by blood collection. B. Blood was
processed using the enhanced ultracentrifugation technique to obtain purified serum,
supernatant-top and supernatant-bottom serum fractions. C. HL-1 cells were subjected to
hypoxia and were treated with serum samples collected from Zucker Lean and Zucker Fatty
rats. HL-1 cells were treated with buffer (control), purified serum, supernatant-bottom or
supernatant-top fractions, administered at 1 hour before the onset of hypoxia, re-administered
at the onset of hypoxia (black arrows) and maintained throughout 2.5 hours of hypoxia. Cell
death was measured 20 hours after reoxygenation. D. In additional experiments, HL-1 cells
were treated with the supernatant-top fraction under normoxic conditions. Green boxes
represent bilateral femoral artery occlusion. Blue boxes represent sample treatments for HL-1
cells. Checked blue box represents treatment with supernatant-top fraction only. White arrows
denote centrifugation or filtration steps.  RIPC, remote preconditioning. 
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HL-1 cell treatment were the same as in Chapter 6.  Briefly, Zucker Lean and Zucker 
Fatty rats underwent the standard remote preconditioning stimulus, consisting of 
bilateral femoral artery occlusion (4x 5-minute ischemic and 5-minute reperfusion). 
Immediately following the last period of femoral artery reperfusion, blood was collected 
centrifuged to isolate the serum, see Figure 7-1A.  Serum was purified by centrifugation 
at 20,000 xG and filtered (0.2µm).  The enhanced ultracentrifugation exosome isolation 
technique described in Chapter 6, section 3.6 was used to fractionate the serum into 
three phases; pellet, supernatant-bottom and supernatant-top, see Figure 7-1B.  HL-1 
cardiomyocytes were treated with purified serum, supernatant-top and supernatant-
bottom, see Figure 7-1C.  The pellet was excluded from analysis based on our previous 
evidence that this fraction had no protective effect against hypoxia/reoxygenation in 
Sprague Dawley experiments.  
3.5 Supplemental Experiments: Treatment with the Supernatant-top Fraction Under 
Normoxic Conditions  
In order to pursue an unexpected observation made in the protocol described 
above, supplemental experiments were performed in which we investigated the effect of 
treatment with supernatant-top fraction obtained from Zucker Lean and Zucker Fatty 
rats on cardiomyocytes under normoxic conditions.  HL-1 cells were treated with the 
supernatant-top fraction in a manner that was designed to mimic the timing and 
conditions of the hypoxia-reoxygenation protocol (see Figure 7 – 1D); treatment was 
initiated by replacing the medium in each culture dish with 3 mL of fresh Claycomb 
medium supplemented with samples of the supernatant-top fraction for 1 hour, and was 
continued by replacing Claycomb culture media with 3 mL serum-free media 
supplemented with the top fraction.  After 2.5 hours, the culture media was replaced 
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with 3 mL serum-free media without supplementation.  Cell viability was assayed with 
trypan blue 20 hours later, as described in Chapter 5, section 3.3. 
3.6 Statistical Analysis 
Data were analyzed with GraphPad Prism software, GraphPad, Inc. (La Jolla, 
CA). Data are presented as means ± SEM.  Endpoints were compared among groups 
by one-way ANOVA.  If significant F-values were obtained by ANOVA, Newman-Keuls 
multiple comparisons test was used to compare treated groups to control. 
4. Results 
4.1 Zucker Lean Rats: Serum and the Supernatant-bottom Fraction Protect HL-1 Cells 
from Hypoxia/Reoxygenation 
As expected, treatment with purified serum and the supernatant-bottom fraction 
from remote preconditioned Zucker Lean rats significantly reduced 
hypoxia/reoxygenation-induced cell death (38 ± 5%, 39 ± 6%, respectively) when 
compared with buffer-treated control cells (48 ± 6% cell death, p<0.05; Figure 7–2).  
Consistent with our hypothesis, treatment with the supernatant-top fraction of serum 
Figure 7–2: HL-1 cells are protected by
treatment with serum and supernatant-
bottom fraction from Zucker Lean rats.
HL-1 cells subjected to
hypoxia/reoxygenation were treated buffer
or with serum samples from remote
preconditioned Zucker Lean rats. RIPC,
remote preconditioning. ns, not significant
vs buffer-treated. n=6/group, *p<0.05
versus Buffer-treated. 
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from remote preconditioned Zucker Lean rats did not have a significant effect on % cell 
death in HL-1 cells subjected to hypoxia/reoxygenation (52 ± 10%, see Figure 7–2). 
4.2 Zucker Fatty Rats: Serum and the Supernatant-bottom Fraction are not Protective – 
the Supernatant-top Fraction Exacerbates Cell Death Caused by 
Hypoxia/Reoxygenation 
In contrast to data obtained in Zucker Lean and Sprague Dawley rats (and as 
expected from our hypothesis), neither the serum nor the supernatant-bottom fraction of 
serum from Zucker Fatty rats had a significant protective effect: mean 
hypoxia/reoxygenation-induced HL-1 cell death was 53 ± 4% and 45 ± 5%, respectively, 
versus 53 ± 4% in buffer-treated cells; see Figure 7 – 3).  Unexpectedly, and contrary to 
our observations made with samples from the other rat strains, treatment with the 
supernatant-top fraction isolated from Zucker Fatty rats caused a significant increase in 
cell death following hypoxia/reoxygenation. 
 
 
Figure 7–3: HL-1 cells are not
protected by treatment with serum
and supernatant-bottom fraction
from Zucker Fatty rats.  HL-1 cells
subjected to hypoxia/reoxygenation
were treated with buffer or serum
samples from remote preconditioned
Zucker Fatty rats. RIPC, remote
preconditioning. ns, not significant vs
Buffer-treated. n=6/group, *p<0.05
versus Buffer-treated. 
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4.3 Zucker Fatty Rats: the Supernatant-top Fraction of Serum does not Exacerbate Cell 
Death under Normoxic Conditions  
We report that under normoxic conditions, treatment with the supernatant-top 
fraction from Zucker Lean rats and Zucker Fatty rats did not have a significant effect on 
cell viability when compared to buffer-treated HL-1 cardiomyocytes.  Cell death 
averaged 15 ± 2%, 17 ± 3% and 10 ± 2%, respectively; p>0.05 by ANOVA, Figure 7–4). 
 
5. Summary 
In summary, we report that, consistent with our predictions, the humoral 
component of remote preconditioning is defective in the Zucker rat model of type-2 
diabetes.  This conclusion is supported by the observation that, while treatment with 
serum and the supernatant-bottom fraction collected from remote preconditioned Zucker  
Lean rats rendered HL-1 cardiomyocytes resistant to hypoxia/reoxygenation, treatment 
with serum and the supernatant-bottom fraction collected from remote preconditioned 
Zucker Fatty rats did not have a significant effect on cell death.  
We suggest that the defect in the humoral mediated protection may be, at least 
partially, caused by a cytotoxic component in the diabetic circulation, present in the 
supernatant-top fraction of serum collected from Zucker Fatty rats.  This conclusion is 
Figure 7–4: The supernatant-top 
fraction of serum does not exacerbate 
cell death in HL-1 cells under 
normoxic conditions. Not significant by 
ANOVA. n=4-7/group. 
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supported by the observation that the supernatant-top fraction from Zucker Lean 
animals had no effect on HL-1 cell death, while the supernatant-top fraction from Zucker 
Fatty rats significantly exacerbated cell death caused by hypoxia/reoxygenation.  
Moreover, we report that the toxic effect of the supernatant-top fraction only occurs in 
the setting of hypoxia/reoxygenation, illustrated by the modest, non-significant effect of 
supernatant-top fraction treatment of HL-1 cells under normoxic conditions.  
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CHAPTER 8: HYPOTHESIS-GENERATING ANALYSIS: INVESTIGATING THE 
COMPONENTS OF BIOACTIVE SERUM FRACTIONS 
1. Rationale 
This dissertation has largely focused on investigating the humoral component of 
remote preconditioning and its function in the setting of type-2 diabetes.  The humoral 
theory suggests that the remote preconditioning stimulus causes the release of 
protective factor(s) into the blood, which are dispersed throughout the circulation.  The 
appeal of identifying an endogenous molecule that can evoke robust cardioprotection is 
obviously compelling; however the humoral factor(s) of remote preconditioning remains 
unknown.  
In general, two strategies have been used to search for the elusive protective 
factor(s) of remote preconditioning; (1) direct identification of the protective factor(s) 
using proteomic or transcriptomic techniques (including 2-dimensional differential gel 
electrophoresis, mass spectrometry or microarray analysis, or by monitor changes in 
protein/RNA abundance in the circulation before and after ischemic conditioning235,257-
264), or (2) characterization of the protective factor(s) by evaluating the ability of sub-
fractions of serum/plasma or tissue effluent to reduce infarct size or attenuate 
cardiomyocyte death.51-53  For example, Shimizu et al. processed plasma from remote 
preconditioned rabbits and humans by dialysis (12-14kDa cut-off membrane) and 
reverse phase chromatography with a C18 Sep Pak column, and provided evidence that 
protection is afforded by a hydrophobic molecule(s) smaller than 15kDa.  
In Chapters 5, 6 and 7, we used filtration followed by ultracentrifugation 
techniques to isolate the protective component of serum from remote preconditioned 
rats.  Based on our hypothesis that the protective molecule(s) are contained within 
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exosomes, we devised an exosome ultracentrifugation isolation technique which 
sequestered an exosome-rich sub-fraction of the serum that transferred protection to 
HL-1 cardiomyocytes.  Unexpectedly, we also isolated a component of serum from 
diabetic rats that exacerbates cell death caused by hypoxia/reoxygenation.  As such, 
the objective of this hypothesis-generating chapter is two-fold.  Our first aim was to 
interrogate the particle content (including, but not limited to, exosomes) of serum 
fractions produced by the enhanced ultracentrifugation technique with nanoparticle 
tracking analysis (conducted by Systems Biosciences Inc. Palo Alto, CA), and obtain 
preliminary insight into the effect of strain (Sprague Dawley, Zucker Lean, Zucker Fatty) 
and treatment (RIPC versus sham) on particle concentration and size.  We hypothesize 
that our enhanced ultracentrifugation technique will facilitate the isolation of differential 
exosome populations involved with communicating protection.  More specifically, we 
speculate that: (1) the supernatant-top fraction, presumed to be exosome-poor by 
immunoblot analysis of classic exosome markers (Chapter 6), will be depleted of 
particles in all samples irrespective of strain or treatment; (2) the particle concentration 
will be greater in the protective fractions (serum and supernatant-bottom) obtained from 
remote preconditioned Sprague Dawley and Zucker Lean rats versus strain-matched 
shams, while, in contrast, (3) particle concentrations will be comparable in serum and 
supernatant-bottom fractions obtained from remote preconditioned versus sham-
operated Zucker Fatty rats.  In our second aim, we propose that the high-force 
ultracentrifugation used in our protocols may facilitate the detection of differential protein 
expression by mass spectrometry and, thus, the discovery of novel protective 
candidates.  Thus, in collaboration with Dr. Xuequn Chen, we conducted exploratory 
mass spectrometry of the serum fractions, with the goal of revealing possible 
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differences in abundance of proteins between treatment groups. 
2. Materials 
See Materials sections from Chapter 4 and 5.  
3. Methods 
3.1 Remote Preconditioning and Serum Collection 
Refer to Chapters 5 section 3.4. 
3.2 Samples Analyzed 
Nanoparticle tracking analysis and mass spectrometry were used to compare 
particle content and protein profiles between treated and untreated groups in Sprague 
Dawley and Zucker cohorts (see Table 8-1).  As discussed in Chapter 6, serum samples 
were obtained following centrifugation at 20,000 xG, while the top and bottom fractions 
were collected after filtration through a 200 nm membrane and ultracentrifugation at 
300,000 xG. 
 
Samples were analyzed by Nanoparticle Tracking Analysis and tandem mass spectrometry. 
n=1/group, unless indicated otherwise. 
 
Table 8–1: Analysis Sample List  
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3.3 Nanoparticle Tracking Analysis 
Particle populations were characterized by System Biosciences, Inc. (Palo Alto, 
CA) with nanoparticle tracking analysis using a NanoSight LM10 (NanoSight, 
Amesbury, United Kingdom).  The Nanosight visualizes particle movement in solution 
with an ultramicroscope, which detects scattered light.  Nanoparticle tracking analysis 
calculates the diameter of individual particles which is proportional to the random 
movement of the particle in solution, otherwise known as Brownian motion.265  Diameter 
measurements were tabulated in 1-nanometer increments, for each size increment, the 
particle concentration (number/mL) was quantified.  All samples were analyzed in 
triplicate.  Given our focus on exosomes, analysis was limited to particles within the size 
range of exosomes (0-200 nm).  Importantly, however, nanoparticle tracking 
analysis detects particles in solution without discrimination, and thus includes 
non-exosome vesicles and protein aggregates: i.e., data reflect particle (rather than 
exosome) sizes and concentrations.  
3.4 Sample Preparation for Mass Spectrometry 
Samples were processed and analyzed by mass spectrometry as described 
previously.266  Serum and supernatant-bottom samples were first depleted of abundant 
plasma proteins using the Pierce Albumin/IgG Removal Kit (ThermoFisher Scientific, 
Waltham, MA) according to the manufacturer’s protocol.  Using this method, Blue dye 
and Protein A, which are conjugated to agarose resin in the stationary phase of the 
column, bind and sequester albumin and immunoglobulin G, respectively.  Serum and 
supernatant-bottom samples were then separated by SDS-PAGE. 
Samples were prepared for mass spectrometry by Dr. Xuequn Chen. Briefly, the 
gels were stained with GelCode Blue stain (ThermoFisher Scientific, Waltham, MA), 
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washed with ammonium bicarbonate, reduced in 10 mM DTT and alkylated with 55mM 
iodoacetamide.  Proteins were digested overnight with four proteases: Lys-C, trypsin, 
Glu-C, and chymotrypsin.  Supernatant-top fraction samples had low protein 
concentration and required concentration by overnight acetone precipitation.  Pellets 
were resuspended in 50 mM ammonium bicarbonate, reduced in 5 mM Tris(2-
carboxyethyl)phosphine and alkylated with 25 mM methyl methanethiosulfonate. Protein 
was digested overnight with trypsin.  
3.5 Mass Spectrometry 
Mass spectrometric analysis using nanoLC-MS/MS was kindly conducted by Dr. 
Chen.  Peptides were separated with reverse-phase chromatography through a C18 
column with the Dionex Ultimate HPLC system (ThermoFisher Scientific, Waltham, MA). 
MS and MS/MS spectra were acquired on an Applied Biosystems QSTAR XL mass 
analyzer, MASCOT 2.4.0 (Matrix Science, Inc. Boston, MA) was used to search the 
National Center for Biotechnology Information non-redundant database, and the 
outcomes were analyzed using Scaffold 4.6.1 software (Proteome Software, Inc. 
Portland, OR).  The minimum requirement for identifying a peptide was set at 90% 
accuracy and two unique peptides were required to identify a protein.  Minimum 
requirement for protein identification was set at 50% accuracy (threshold was set low to 
increase the output of identified proteins).  Protein abundance was reported as total 
spectrum count, and comparisons were made between groups and reported as fold 
change (see below). In the instance that the initial value was zero and the initial value 
was larger than zero, fold change was reported as the final value. 
3.6 Statistical Analysis 
For each cohort and fraction, nanoparticle size is reported as the mode of the 
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replicates + SEM, while particle concentration (number/mL) is reported as both a 
frequency distribution (mean values + SEM for particles ranging from 0-200 nm) and 
mean total concentration + SEM.  
Given the small number of independent samples (n=1-2 per group) probed in 
these exploratory experiments, statistical comparisons among cohorts and between 
serum fractions were not performed.  However, qualitative comparisons of nanoparticle 
concentration and protein abundance between groups were made by calculating fold 
change, defined as:  
Fold Change = (Value 2 – Value 1)/Value 1 
4. Results 
4.1 Nanoparticle Tracking Analysis: Characterizing the Particle Population in Sprague 
Dawley Samples 
As expected, nanoparticles were detected in the serum and supernatant-bottom 
samples from Sprague Dawley rats (Figure 8-1).  In addition, the concentration of 
particles was ~1.0 to 1.4-fold higher in samples from rats that underwent RIPC when 
compared with shams: for serum, mean concentrations were 2.0 x1012 versus 1.0 x 1012 
particles/mL (a 1.0-fold increase, data not shown) and, for the supernatant-bottom 
fractions, concentrations were 2.2 x 1012 versus 9.0 x 1011 particles/mL (a 1.4-fold 
increase (see Figure 8–1 B, D).  Particle size in the supernatant-bottom fraction was 
comparable in the two cohorts, with modes of 60 and 58 nm. 
Contrary to our hypothesis, the supernatant-top fractions (presumed to be devoid 
of exosomes based on immunoblot analysis) contained particles, with mean 
concentrations of 1.4 x 1011 particles/mL in samples from sham-operated animals 
versus 1.3 x 1012 particles/mL in samples from remote preconditioned rats (8.3-fold 
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larger concentration, see Figure 8–1B, D).  The mode of the particle size in this fraction 
ranged from 60 nm to 52 nm, see Figure 8–B, D.  
 
4.2 Nanoparticle Tracking Analysis: Characterizing the Particle Population in the Zucker 
Lean Fractions  
For samples obtained from the Zucker Lean cohort, nanoparticle concentrations 
were of a comparable magnitude to those observed in samples from Sprague Dawley 
 
Figure 8–1. Nanoparticle tracking analysis of samples from Sprague Dawley rats. Serum
and the supernatant-top and -bottom were analyzed with nanoparticle tracking analysis to count
and measure the size of particles in solution. A. Screenshot from nanosight video and B.
analysis of sham samples. C. Screenshot from nanosight video and D. analysis of samples from
remote preconditioned samples. 3 replicates per sample, n=1 independent samples/group. 
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rats.  However, the 1.1 to 8.3-fold increase in nanoparticle concentration seen with 
RIPC in Sprague Dawley rats was not observed in fractions harvested from Zucker 
Lean rats.  Rather, nanoparticle concentrations in serum, the  supernatant-bottom 
fractions and the supernatant-top fractions were 0.15-fold lower, 0.9-fold lower (see 
Figure 8–2), and equivalent (0.04-fold higher, see Figure 8-2) in RIPC samples versus 
 
Figure 8–2: Nanoparticle tracking analysis of samples from Zucker Lean rats. The top and
bottom fractions of serum were analyzed with nanoparticle tracking analysis to count and
measure the size of particles in solution. A. Screenshot from nanosight video and B. analysis of
sham samples. C. Screenshot from nanosight video and D. analysis of samples from remote
preconditioned samples. 3 replicates per sample, n=1 independent samples/group. 
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shams.  Particle sizes were qualitatively larger in the Zucker Lean cohort, with modes 
ranging from 67-74 nm (Figure 8–2).  
4.3 Nanoparticle Tracking Analysis: Characterizing the Particle Population in the Zucker 
Fatty Fractions 
In Zucker Fatty rats, nanoparticle concentrations in the serum-bottom fractions 
were similar in magnitude to those observed in the other two strains, with a 0.17-fold 
lower concentration of particles present following remote preconditioning when 
compared with sham-controls.  In contrast, nanoparticle concentration in the 
supernatant-top fraction of sham-control rats was orders of magnitude higher than seen 
in all other samples from all cohorts (3.9 x 1013 particles/mL), while the mean 
concentration in the remote preconditioned top fraction was 14-fold lower at 2.6 x 1012 
particles/mL.  Particle sizes in the supernatant-top fraction were 63 nm in both groups 
(comparable to values observed in Sprague Dawley cohorts), but were qualitatively 
larger in the supernatant bottom fractions (modes of 75-88 nm, Figure 8-3). 
4.4 Mass Spectrometry: Effect of Remote Preconditioning on Serum Protein Expression 
in Sprague Dawley and Zucker Rats 
For Sprague Dawley rats, MS/MS analysis revealed increases in abundance of 
20 proteins in serum and 23 proteins in the protective supernatant-bottom fraction, 
harvested following RIPC when compared with sham controls.  Of the twenty serum 
proteins, four proteins also had increased abundance in the supernatant-bottom 
fraction, listed in Table 8–2A, B.  These proteins include: Apolipoprotein E, which was 
increased 1-fold in the remote preconditioned serum and 1.3-fold in the supernatant-
bottom fraction compared to sham control samples.  Hemoglobin subunit beta-1 was 
increased in both the serum and supernatant-bottom fraction by 0.3-fold.  
Carboxylesterase C1 abundance was greater in the serum and supernatant-bottom 
77 
 
fraction by 0.2-fold and 0.1-fold, respectively.  Ceruloplasmin was increased by 0.1-fold 
and 0.2-fold in the serum and supernatant-bottom, respectively.  To further interrogate 
the involvement of these proteins with remote preconditioning, we compared the 
abundance of these protective candidates in the supernatant-bottom fraction from 
Figure 8–3: Nanoparticle tracking analysis of samples from Zucker Fatty rats. The top and
bottom fractions of serum were analyzed with nanoparticle tracking analysis to count and
measure the size of particles in solution. A. Screenshot from nanosight video and B. analysis of
sham samples. Inset graph is a larger scale representation of the Frequency distribution. C.
Screenshot from nanosight video and D. analysis of samples from remote preconditioned
samples. Inset graph is a larger scale representation of the Frequency distribution.3 replicates
per sample, n=1 independent samples/group. 
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Zucker Lean and Zucker Fatty rats, Table 8–2C, D, respectively.  Consistent with the 
concept that protective proteins will be depleted or deficient in diabetic serum, all four 
proteins have lower expression in the supernatant-bottom sample from Zucker Fatty 
rats compared to Zucker Lean rats; Apolipoprotein-E abundance is decreased from 4 to 
3 (~0.3-fold decrease), hemoglobin subunit beta-1 is decreased from 4 to 0.5 (~0.9-fold 
decrease).  Carboxylesterase C1 abundance is decreased from 12 to 6 (0.5-fold 
decrease) and ceruloplasmin is decreased from 15.5 to 14.5 (0.1-fold decrease). 
Table 8–2: Mass spectroscopy reveals differential abundance of proteins 
A list demonstrating proteins with an increased abundance in serum from remote preconditioned 
Sprague Dawley compared to sham controls. Also listed are proteins with increased abundance in the 
supernatant-bottom fraction that also overlap with serum proteins. B. Venn diagram demonstrating the 
overlap between the proteins that had increased abundance in both the serum and supernatant-bottom 
from remote preconditioning in Sprague Dawley rats. Additionally, the abundance of the four proteins 
that were commonly increased by remote preconditioning were listed for the supernatant-bottom 
fraction from C. Zucker Lean rats and D. Zucker Fatty rats. n=1/group for Sprague Dawley samples. 
n=2-3/group for Zucker samples. 
Finally, with the interest of identifying proteins that may be involved with the toxic 
effect of the supernatant-top sample from Zucker Fatty rats, we compared the 
differences in protein abundance in the supernatant-top fraction between the two Zucker 
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strains. Initially we uncovered 86 proteins that had an increased (42) or decreased (44) 
abundance in the Zucker Fatty rats compared to the Zucker Leans.  We eliminated 15 
proteins from this list that were identified as protective candidates from the Sprague 
Dawley samples.  Of the remaining 71, ten proteins with the largest increase in 
abundance and ten with the largest decrease in abundance are tabulated in Table 8–3. 
Table 8–3: Potential toxic candidates in the supernatant-top sample from Zucker 
Fatty rats. 
5. Summary 
In summary, we report qualitative results on the size and concentration of 
nanoparticles (under 200 nm diameter) in serum samples from Sprague Dawley, Zucker 
Lean and Zucker Fatty rats. Despite the exploratory nature of these experiments, three 
notable observations were made.  First, contrary to our hypothesis, nanoparticle 
tracking analysis demonstrated that high concentrations of exosome-sized particles 
were present in the supernatant-top fractions obtained from all cohorts.  This was 
unexpected, based on the absence of classic exosome markers as detected by 
immunoblotting, in this fraction (see Chapter 6).  Second, although RIPC was 
associated with an increase in nanoparticle concentrations in Sprague Dawley rats, this 
The list demonstrates proteins with the largest differential abundance in the supernatant-top fraction 
from Zucker Fatty rats compared to Zucker Lean.  n=2-3/group for Zucker samples. 
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was not a consistent finding.  In our preliminary analysis, RIPC was not accompanied by 
an increase in nanoparticle concentration in serum and serum fractions obtained from 
Zucker Lean rats – a strain in which RIPC was cardioprotective.  Finally, hyperglycemic 
Zucker Fatty rats appear to be characterized by nanoparticle concentrations that are 
orders of magnitude higher than those observed in the normoglycemic strains, an 
observation that appears to be consistent with previously published findings.267  Our 
preliminary MS/MS analysis demonstrates that there are proteins (4) common between 
the serum and supernatant-bottom samples which may be involved with 
cardioprotection through upregulation by remote preconditioning.  Data in the Zucker 
cohorts supports these findings, suggesting that abundance of these proteins is greater 
in supernatant-bottom fraction from Zucker Lean rats compared to Zucker Fattys.  
Additionally, we have interrogated the supernatant-top fraction to identify potential toxic 
factors in the serum from Zucker Fatty rats by comparing the proteomic profile to the 
supernatant-top fraction from Zucker Lean rats. 
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CHAPTER 9: DISCUSSION 
1. Summary of Results 
The present study tested three hypotheses with two complementary models; 
analysis of remote preconditioning in vivo and in vitro.  We made four novel 
observations: 
i. Remote preconditioning, normally protective against myocardial 
ischemia/reperfusion injury, is ineffective in the Zucker Fatty rat model of 
early-stage type-2 diabetes. 
ii. Exosomes isolated with the traditional ultracentrifugation technique do not 
transmit protection. An enhanced ultracentrifugation technique is necessary to 
sequester a protective sub-fraction from remote preconditioned serum. 
iii. Exosomes may be involved with remote preconditioning, but are not sufficient 
for remote preconditioning. 
iv. The failure of remote preconditioning is, at least partially, caused by a defect 
in the humoral component of cardioprotective signaling. 
2. Remote Preconditioning in Type-2 Diabetes: Current Knowledge and New 
Contributions 
Remote preconditioning is a candidate treatment for acute myocardial infarction.  
Despite overwhelming experimental support and obvious clinical advantages, 
translation of remote preconditioning has been unsuccessful.  As discussed in Chapter 
1, diabetes may be a primary cause of attenuated clinical efficacy.  
Although the evidence in type 1 diabetes is mixed, ischemic preconditioning and 
postconditioning are consistently attenuated or lost in rodent models of type-2 diabetes.  
Additionally, clinical evidence supports that diabetes causes resistance to 
cardioprotection by ischemic conditioning.132,133 Remote preconditioning has 
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considerable mechanistic overlap with ischemic pre- and post-conditioning in terms of 
protective trigger, signaling and intracellular effectors, which might suggest that there is 
a similar defect in remote preconditioning the setting of diabetes. 
2.1 Infarct Reduction by Remote Preconditioning In Vivo 
In Chapter 2, we evaluate the efficacy of remote preconditioning in the setting of 
type-2 diabetes in vivo.  Of the innumerable studies in the field of ischemic conditioning, 
ten have investigated the cardioprotective efficacy in the setting of type-2 diabetes, five 
focusing on ischemic preconditioning and five on ischemic postconditioning (Table 1 – 
1).  These investigations have reported a common finding: that ischemic conditioning is 
impaired or eliminated in models of type-2 diabetes.  Accordingly, we hypothesized that 
the cardioprotective efficacy of remote preconditioning is reduced a model of type-2 
diabetes. 
In the current study, using the Zucker rat model of type-2 diabetes and an in vivo 
model of myocardial ischemia/reperfusion, we demonstrated that the cardioprotective 
efficacy of remote preconditioning is eliminated in type-2 diabetes.  This is the first study 
investigating remote preconditioning in the setting of type-2 diabetes in vivo.  These 
results are consistent with Kristiansen et al. and Katakam et al., who reported that 
ischemic preconditioning (as opposed to remote preconditioning) did not reduce infarct 
size in Zucker Fatty rats.106,107  Our results are also supported by studies in other 
models of type-2 diabetes including Goto Kakizaki rats,106,110,112,113 db/db mice,107,108 
ob/ob mice100,111,114 and WOWK rats with metabolic syndrome109 that report impaired or 
abolished cardioprotection.  Moreover, our data is consistent with two studies that 
evaluated remote POST-conditioning123 and remote PER-conditioning268 in the 
streptozotocin-induced model of type 1 diabetes. 
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2.2 Defect of Remote Preconditioning: Hyperglycemia and Ischemic/Reperfusion 
Sensitivity 
The reason that cardioprotection is impaired in the setting of type-2 diabetes is 
unclear.  A number of preclinical studies have implicated hyperglycemia and 
sensitization to ischemia/reperfusion, however this evidence is inconsistent.  
Hyperglycemia, the primary clinical manifestation of type-2 diabetes, may negatively 
impact the efficacy of ischemic preconditioning269-272, postconditioning108 and remote 
preconditioning.273  Additionally, clinical evidence suggests that the myocardium is 
sensitized to ischemia/reperfusion in the setting of diabetes,81,82 however evidence from 
preclinical studies is less convincing.22  Hyperglycemia upon admission for AMI 
treatment is correlated with mortality,274,275 which is correlated with infarct size. Lastly, 
there is evidence that hyperglycemia is correlated with increased area at risk 276 which 
may cause resistance to ischemic conditioning.277  Accordingly, we hypothesized that 
hyperglycemia sensitizes the myocardium to ischemia/reperfusion and reduces the 
efficacy of remote preconditioning.  
Our results did not support this hypothesis.  First, we found that infarct size 
between the control groups from Zucker Fatty and Zucker Lean cohorts was 
comparable, suggesting that neither type-2 diabetes, nor hyperglycemia per se, 
increase the sensitivity of the myocardium to ischemia/reperfusion.  Second, infarct size 
in the remote preconditioned groups from Zucker Fatty and Zucker Lean rats did not 
correlate with blood glucose, which we would have expected if hyperglycemia 
attenuated protection.  Lastly, area at risk was comparable between all groups. 
The effect hyperglycemia and type-2 diabetes have on resistance to ischemic 
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conditioning in preclinical models of diabetes is controversial.  Kersten et al. illustrated 
that the severity of hyperglycemia plays a critical role in the attenuation of ischemic 
preconditioning, however Gu et al.278 and Wagner et al.109 describe impaired ischemic 
conditioning even with mild-moderate hyperglycemia.  Bayanyai et al. report that acute 
hyperglycemia in healthy (non-diabetic) rats impaired remote preconditioning, 
suggesting that hyperglycemia per se may cause resistance to cardioprotection in the 
setting of diabetes.273  Nonetheless, we report that remote preconditioning is impaired in 
type-2 diabetes, despite: (i) no evidence of exacerbation of ischemic/reperfusion injury, 
(ii) mild hyperglycemia and (iii) treatment with a robust conditioning stimulus. 
3. Diabetes and the Humoral Component of Remote Preconditioning: Current 
Knowledge and New Contributions 
By definition, remote preconditioning is capable of overcoming a spatial barrier to 
evoke protection.  Currently, humoral signaling is regarded as one of two central 
components theorized as a mediator of cardioprotection, although the mechanism has 
not been fully elucidated.  Exosomes are extracellular vesicles recognized for their role 
in cell-to-cell communication and could hypothetically play an important role in the 
humoral component of remote preconditioning 
The humoral component is supported by convincing evidence that protection 
against ischemia/reperfusion can be transferred in the blood from preconditioned 
animals (or perfusion buffer from preconditioned tissues) to naïve animals or tissues.  
Theoretically, the remote preconditioning stimulus releases protective factors into the 
circulation, which are delivered to distant, at-risk tissues.  The exact mechanisms 
involved are unclear, however a better understanding will surely help improve protective 
efficacy and clinical translation.  Exosomes are an obvious candidate for carrying 
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protective signals through the circulation; capable of protecting bioactive cargo in the 
harsh extracellular environment and targeted delivery of bioactive molecules.163  Indeed, 
exosomes have received attention for cardioprotective capabilities, however evidence of 
this function are based on studies in stem cell treatment of myocardial infarction.  Only 
recently have exosomes been implicated in remote preconditioning and evidence of 
their involvement is limited200 and nebulous.236  We propose that exosomes are an 
integral factor in the humoral component of remote preconditioning.  Moreover, we 
hypothesize that this mechanism is compromised in the setting of type-2 diabetes, 
which contributes to impaired cardioprotection. 
3.1 Exosome Isolation: Traditional and Enhanced Ultracentrifugation Isolation 
Techniques 
In 2014, Giricz et al. reported the first evidence that exosomes are involved in the 
transfer mechanism of remote preconditioning.200  In this seminal study, vesicles were 
obtained from the coronary effluent of ischemic preconditioned, buffer perfused hearts 
using the traditional ultracentrifugation protocol for isolating exosomes, which resulted in 
an exosome-marker rich pellet and an exosome-depleted coronary effluent.  Treatment 
with the exosome-rich sample was sufficient to evoke protection against 
ischemia/reperfusion in buffer perfused hearts, while the exosome-depleted effluent had 
no effect.  Our aim was to investigate the role of exosomes in the cardioprotective 
humoral signaling of remote preconditioning.  
In preliminary experiments, we used the traditional ultracentrifugation technique 
to collect serum exosomes.  In contrast to the Giricz study, we found that the exosome-
rich pellet was not protective, whereas the exosome-depleted serum provided 
significant protection.  To explain this disparity, we hypothesized that the traditional 
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ultracentrifugation protocol does not adequately sediment cardioprotective exosomes 
from serum, a concept supported by previous studies.19,247  We modified the isolation 
protocol by increasing radial force and duration to optimize exosome sedimentation and 
facilitate depletion of exosomes from serum.248,279  Ultimately, the enhanced 
ultracentrifugation protocol fractionated serum into three phases; a pellet (rich with 
exosome markers) and a biphasic supernatant.  The top half of the supernatant was 
devoid of exosome markers (supernatant-top) and the bottom half was rich with 
exosome markers (supernatant-bottom). 
The next step was to test the protective capacity of each sample as a treatment 
against hypoxia/reoxygenation injury in cardiomyocytes.  First, we report that transfer of 
the exosome-rich supernatant-bottom fraction to HL-1 cardiomyocytes attenuated cell 
death, suggesting that, consistent with the Giricz study, exosomes play a role in remote 
preconditioning.  Second, regardless of exosome content, the remaining fractions did 
not provided protection, suggesting that exosomes are not sufficient for protection.  
These results indicate that enhanced ultracentrifugation technique may separate 
functionally distinct populations of exosomes.  As discussed in Chapter 2 however, it is 
important to note that ultracentrifugation isolation sediments protin aggregates and 
other particles in addition to exosomes and based on these results we cannot 
unequivocally conclude that exosomes are responsible for protection.13,280 
3.2 Protection with the Supernatant-bottom Fraction of Sham Serum 
We report that the supernatant-bottom fraction collected from sham operated 
Sprague Dawley rats transmitted modest but significant protection against 
hypoxia/reoxygenation-induced cell death in HL-1 cardiomyocytes.  These unexpected 
results may be an example of “remote preconditioning of trauma” described by Ren et 
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al., who reported that an abdominal incision caused significant cardioprotection, which 
was not additive with traditional/ischemic remote preconditioning.281,282  Accordingly, in 
our experimental protocol, the femoral artery isolation surgical procedure may initiate 
“remote preconditioning of trauma”.  The finding that the supernatant-bottom sample – 
and not unfractionated serum – evoked protection suggests that exosomes are involved 
with the signaling component of “remote preconditioning of trauma”.  Alternatively, 
previous studies have reported cardioprotective effects of exosomes in the absence of a 
remote-ischemic or traumatic preconditioning stimulus.197-199,236  For example, Vicencio 
et al. reported that, for reasons that were not elucidated, exosomes collected from sham 
subjects had the same protective capacity as those collected from remote 
preconditioned subjects.236 
3.3 The Effect of Type-2 Diabetes on the Humoral Component of Remote 
Preconditioning 
The infarct sparing efficacy of ischemic preconditioning and postconditioning is 
exclusively attenuated or eliminated in animal models of type-2 diabetes.  The majority 
of these studies have focused on the concept that the defect in ischemic conditioning is 
caused by the effect that diabetes has on the myocardium.100,108,110-112,250-256  A 2012 
study by Jensen and colleagues, was the first to investigated the effect of type-2 
diabetes on the humoral component of remote preconditioning.  Using serum harvested 
from human subjects and applied to buffer-perfused rabbit hearts, the authors reported 
that the diabetes-associated defect in transferred protection was only apparent in in 
serum from diabetic patients with peripheral neuropathy.124  The same group also 
reported that, through humoral mediated signaling, diabetes reduces the susceptibility 
of healthy myocardial tissue to ischemia/reperfusion, however this phenomenon 
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occurred independent of remote preconditioning.283  We postulated that a defect in the 
humoral component contributes to the failure of remote preconditioning in the setting of 
type-2 diabetes.  To test this hypothesis, we treated cardiomyocytes with serum and 
fractionated serum samples collected from diabetic Zucker Fatty rats subjected to 
remote preconditioning. We report two primary observations:  
Consistent with our hypothesis, (1) treatment with serum and the supernatant-
bottom fraction obtained from remote preconditioned Zucker Fatty rats did not 
communicate protection to cardiomyocytes subjected to hypoxia/reoxygenation. Ours is 
the first study providing evidence that a defect in humoral signaling contributes to 
attenuated cardioprotection by remote preconditioning.  Jensen et al. reported that 
attenuated protection is dependent on peripheral neuropathy.  Zucker Fatty rats 
progressively develop peripheral neuropathy,284  however we used a model of early-
stage diabetes, which suggests that the defect is independent of this pathology.  A 
subsequent study by the same group observed improved myocardial functional recovery 
following ischemia/reperfusion after treatment with plasma dialysate from sham and 
remote preconditioned diabetic subjects.283 
Remarkably, (2) we also report that the supernatant-top fraction of serum from 
Zucker Fatty rats exacerbated cardiomyocyte death caused by hypoxia/reoxygenation.  
Furthermore, this toxicity is dependent on hypoxia/reoxygenation, as the supernatant-
top fraction had no effect on cells in a normoxic environment.  These findings are 
unexpected, considering that in Zucker Fatty rats (i) the ischemia/reperfusion injury is 
not exacerbated and (ii) the unfractionated serum has no effect on cell viability. In other 
words, the toxic factors present in the diabetic serum only become apparent when the 
serum is fractionated.  Diabetes is an inflammatory disease, with increased expression 
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of circulating cytokines, some of which have been implicated in cardiomyocyte 
apoptosis including interleukin-1β285 and tumor necrosis factor-α286, which may 
contribute to the injurious effects of the supernatant-top fraction. Hyperlipidemia is 
commonly associated with type-2 diabetes and models of type-2 diabetes, including 
Zucker Fatty rats; studies have demonstrated that a hyperlipidemic diet sensitize the 
myocardium to ischemia/reperfusion287,288 or encourage resistance to ischemic 
preconditioning.289  Importantly, there is evidence that certain fatty acids promote 
apoptosis in cultured cardiomyocytes.290 
3.4 Nanoparticle Tracking Analysis 
Interrogation of the particle content of our samples was critical, particularly 
because we used a novel isolation technique that has not been characterized. We used 
nanoparticle tracking analysis, a common technology used for detecting exosomes, to 
measure particle size and concentration.  Based on our data, we were able to make one 
important conclusion; that exosome-sized particles were present in all of the 
fractionated serum samples – including the presumably exosome-poor top fraction - 
from all rat strains.  This finding corroborates our previous conclusions that (1) 
exosomes may be necessary for remote preconditioning and that (2) exosomes are not 
necessarily sufficient for protection.  Lastly, these results suggests that (3) the 
enhanced ultracentrifugation isolation technique does not sediment all particles from the 
serum. 
Vicencio et al. reported that exosome release is stimulated by a remote 
preconditioning stimulus and that particle concentration correlates with protection.236 
Giricz et al. also report indirect evidence that exosome concentration is increased by an 
ischemic conditioning stimulus.200  Based on our observations that particle 
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concentration was increased in Sprague Dawley and reduced in Zucker Lean rats, it is 
unclear how remote preconditioning effects exosome release. Moreover, in our 
experiments, particle concentration does not correlate with protection, an observation 
supported by the lack of protection from treatment with the supernatant-top fraction and 
pellet, both of which contain particles. Importantly, nanoparticle tracking analysis cannot 
not distinguish exosomes from non-exosome particles. Accordingly, we predict that the 
particles present in this fraction are non-exosome particles, based on immunoblotting 
evidence that this sample is depleted of classic exosome markers. Interestingly, very-
low density lipoprotein particles are less dense than exosomes (1.006 g/mL291 for very-
low density lipoprotein versus 1.13-1.19 g/mL for exosomes292) and may remain in the 
supernatant following ultracentrifugation.  
4. Qualitative Proteomic Characterization: Targeting the Humoral Component of 
Remote Preconditioning 
Currently, the identity – and molecular nature – of the protective humoral 
factor(s) in remote preconditioning remains unknown. Hepponstal et al.257,263, Pang et 
al.258, Hibert et al.260,261, Helgeland et al.262 Lang et al.259 have explored the circulation 
for proteins that are differentially expressed in response to ischemic conditioning. Using 
functional techniques to assay for protection (by treating naïve tissues with serum or 
perfusion buffer collected from ischemic conditioned tissue that has been filtered) the 
humoral factor has been described as being small (between 3.5 and 15 kilo Daltons) 
and hydrophobic.51-53  
Similar to previous reports, we used mass spectroscopy to detect changes in 
abundance of circulating proteins. In contrast however, we used our novel method of 
prolonged ultracentrifucation to isolate a protective fraction of the serum, and theorized 
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that this would facilitate detection of changes in abundance of candidate protective 
protein(s). After initial trouble-shooting and analysis of serum and serum fractions 
obtained from Sprague Dawley rats, we compared the changes in expression between 
Zucker Lean rats, that have intact protective humoral signaling, and Zucker Fatty rats 
where the humoral component is defective. Lastly, with the interest of identifying toxic 
circulating factors, we have compared the protein abundance in the supernatant-top 
fraction of Zucker Fatty and Zucker Lean rats. 
Beginning with the Sprague Dawley cohort, we found 20 proteins in the 
unfractionated serum and 23 proteins in the supernatant-bottom fraction that were 
upregulated.  Four of these candidate proteins were commonly upregulated in both the 
serum and supernatant-bottom fraction and, furthermore, all 4 proteins had increased 
expression in the Zucker Lean rats compared to Zucker Fattys; apolipoprotein-E, 
hemoglobin subunit beta-1, carboxylesterase 1C and ceruloplasmin. There is evidence 
that ceruloplasmin may protect against ischemia/reperfusion induced ventricular 
fibrillation, and apolipoprotein-E293 and its mimetics have been demonstrated protection 
against brain ischemia.294 Additionally, some evidence suggests that apolipoproteins-E 
is present in exosomes secreted from astrocytes and upregulated in response to 
hypoxia.226 Ceruloplasmin has been discovered in urinary exosomes, in the setting of 
kidney disease. However, there is currently no evidence to suggest that 
carboxylesterase 1C or hemoglobin subunit beta-1 are involved with protective 
signaling. In the supernatant-top fraction, 86 proteins were upregulated or 
downregulated in Zucker Fatty rats compare to Zucker Lean rats. After removing 
protective candidates, identified above, 71 proteins were implicated in the toxic 
component of diabetic serum. It is also worth noting that apolipoprotein B-100, 
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apolipoprotein C-I, III, VI and apolipoprotein E – all common proteins in very low density 
lipoprotein – are more abundant in the supernatant-top fraction compared to the bottom 
fraction in nearly all rat strains, data not shown. This supports the hypothesis that the 
particles present in the supernatant-top fraction are very low density lipoprotein. 
Interestingly, previous data suggest that very low density lipoprotein may exacerbate 
the injury caused by ischemia295 and hypoxia.296 Moreover, type-2 diabetes is 
associated with an increase in circulating VLDL297, which may explain the increased 
particle concentration in the supernatant-top fraction collected from Zucker Fatty rats 
and could contribute to its toxic effect.  
As with all mass spectrometry studies in remote preconditioning, our proteomic 
data are hypothesis generating. While the proteins identified as protective or toxic may 
be involved with remote preconditioning, further investigation will be required to 
implicate the candidates in cardioprotection or toxicity. Importantly, our data do not 
suggest that proteins are exclusively responsible for protection or toxicity. It is possible 
that other molecule types, such as nucleic acids or lipids, may contribute to cell fate . 
Additionally, this technique of mass spectrometry does not detect modification of 
proteins such as phosphorylation or oxidation, which may also contribute to protection 
or toxicity.  
5. Technical Limitations and Merits 
A primary limitation in this study is the inadequacy of experimental techniques, 
such as isolation and quantification methods, in the exosome field, which are inherent 
and well documented.13 To our credit, we enhanced the standard exosome isolation 
technique based on Svedberg kinetics (the forces involved with sedimentation) to 
improve yield and completeness, which resulted in the discovery of two functionally 
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distinct fractions of the serum. Nonetheless, the enhanced ultracentrifugation technique 
probably sacrifices purity for yield, resulting in exosome preparations contaminated with 
non-exosome particles, such as protein aggregates or lipoproteins. A second limitation 
is that, in our model, it is not possible to apply the remote preconditioning stimulus and 
blood withdrawal without tissue manipulation and this possibly stimulating ancillary 
protective signaling such as remote preconditioning of trauma. While our results 
obtained in supernatant-bottom fractions obtained from sham cohorts suggests that 
preconditioning of trauma may have occurred, our results did provide evidence that this 
protective phenomenon communicates through the exosome-rich bottom fraction. The 
third limitation is the use of a cell culture model, where it is unclear how closely 
hypoxia/reoxygenation in vitro mimics AMI in vivo, and, more specifically HL-1 cells (an 
immortal cell line) rather than primary cardiomyocytes.  Nonetheless, we have found 
that HL-1 cells are sensitive to acute hypoxia/reoxygenation and cell death can be 
easily quantified. Importantly, to investigate the humoral component of remote 
preconditioning it is necessary to have naïve (unconditioned) tissue, and using 
immortalized cardiomyocytes reduces the demand for whole animals. Additionally, 
treating cultured cells requires considerably less sample volume, compared with other 
naïve-tissue treatment options (transfer to whole animal or buffer-perfused heart). 
Follow-up studies are required to corroborate our findings with intact biological systems.  
6. Conclusions and Future Directions 
In consideration of our in vivo and in vitro results, we theorize that there is a 
balance of bioactive components in the serum that modulate the severity of 
ischemia/reperfusion.  Convincing evidence has demonstrated that remote 
preconditioning causes the release of beneficial factors, tipping the balance to favor 
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cardioprotection. We further propose that, in the setting of type-2 diabetes, remote 
preconditioning is also associated with the release or activation of factors than may 
increase sensitivity of the myocardium to ischemia/reperfusion: i.e., we demonstrated 
that a sub-fraction of serum harvested from diabetic Zucker Fatty rats exacerbated 
hypoxia-reoxygenation-induced cell death in vitro. This may be mediated by specific 
macromolecules, such as proteins or nucleic acids, or by the post-translational 
modifications, such as oxidation or phosphorylation, of one or more of these 
macromolecules.  Despite a cytotoxic component of serum from Zucker Fatty rats, 
neither in vivo remote preconditioning in this cohort nor application of serum to HL-1 
cells exacerbated cardiomyocyte death – an observation that reinforces the 
aforementioned notion of a balance among bioactive components in the intact serum. 
The major conclusion of this dissertation study is that remote preconditioning is 
ineffective in the Zucker Fatty model of type-2 diabetes due to a defect in the protective 
humoral signaling. Giricz et al. illustrated that exosomes are a critical component in 
cardioprotection by remote preconditioning in ex vivo rat hearts.200  Our data expand on 
this concept, reporting that while exosomes may be necessary, they are not sufficient to 
evoke cardioprotection.  Moreover, the defect in the humoral component of remote 
preconditioning may relate to the balance of bioactive factors in the circulation.  The 
possibility that a toxic factor is present in circulation – and increased in diabetes – may 
provide a foundation for future studies that could advance ischemic conditioning 
technology. 
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ABSTRACT 
REMOTE PRECONDITIONING: EVALUATING THE EFFICACY OF 
CARDIOPROTECTION IN TYPE-2 DIABETES AND EXPLORING THE 
MECHANISTIC ROLE OF EXOSOMES 
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Degree: Doctor of Philosophy 
 Remote preconditioning is a promising and robust treatment for myocardial 
ischemia/reperfusion injury that evokes cardioprotection through endogenous neural 
and/or humoral signaling. A recent study has reported that protective signaling is 
mediated by exosomes through the circulation; however this concept is supported by 
limited and inconsistent evidence. Despite overwhelming success in preclinical studies, 
the efficacy of remote preconditioning in human studies is inconclusive. Importantly, the 
majority of remote preconditioning studies use healthy animal models despite growing 
evidence that comorbidities, such as type-2 diabetes, may negatively influence 
outcomes. Nonetheless, the efficacy of remote preconditioning in the setting of type-2 
diabetes has not been investigated. 
 Using an established model of myocardial ischemia/reperfusion in the Zucker 
model of type-2 diabetes and a model of hypoxia/reoxygenation in cultured HL-1 
cardiomyocytes we tested four hypotheses:  
i. remote preconditioning is ineffective in early-stage type-2 diabetes in vivo; 
ii. the traditional ultracentrifugation technique for exosomes isolating is inadequate 
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to isolate protective factor(s) from remote preconditioning; 
iii. enhanced ultracentrifugation technique for exosome isolation sequesters a 
protective fraction of serum; 
iv. the humoral component of remote preconditioning is defective in type-2 diabetes. 
 In support of Hypothesis I, we demonstrate that remote preconditioning failed to 
reduce infarct size caused by ischemia/reperfusion in the Zucker model of early-stage 
type-2 diabetes. Our results illustrate that the loss in efficacy is not the result of 
hyperglycemia per se nor sensitization of the myocardium to ischemia/reperfusion. 
Subsequently, we sought to isolate a subfraction of serum from remote preconditioned 
rats which contained exosomes that could communicate protection and render HL-1 
cardiomyocytes resistant to hypoxia/reoxygenation-induced cell death. In agreement 
with Hypothesis II, we report that the traditional ultracentrifugation isolation technique 
(100,000 xg for 2 hr) did not isolate the protective component with the exosome-rich 
pellet from serum, suggesting that the protective component remained in the 
supernatant. In accordance with these observations, we enhanced the 
ultracentrifugation technique to improve exosome sedimentation and obtain a protective 
sub-fraction of serum. In agreement with Hypothesis III, the enhanced 
ultracentrifugation technique (300,000 xg for 12 hr) isolated a protective exosome-rich 
supernatant fraction from remote preconditioned serum. However, our enhanced 
ultracentrifugation technique also yielded an additional, exosome-rich pellet  and an 
exosome-depleted fraction, neither of which evoked protection. Lastly, in support of 
Hypothesis IV, we demonstrate that unfractionated serum and the exosome-rich 
supernatant fraction obtained from remote preconditioned diabetic Zucker Fatty rats did 
not protect HL-1 cardiomyocytes from hypoxia/reoxygenation. In conclusion, our results 
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illustrate for the first time that the infarct-sparing efficacy of remote preconditioning is 
abolished in the setting of early-stage type-2 diabetes. We demonstrate that exosomes, 
although not sufficient for protection, may be requisite in the humoral component of 
remote preconditioning.  Finally, we report that the humoral component of remote 
preconditioning is defective in the setting of type-2 diabetes – a defect that may 
contribute to the failure of remote conditioning to limit infarct size in this comorbid 
model.   
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